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Abstract 
 
Altered permeability of the endothelial barrier in a variety of tissues has implications 
both in disease pathogenesis and treatment. Glucocorticoids are potent mediators of 
endothelial permeability and this forms the basis for their heavily-prescribed use as 
medications to treat ocular disease. However, the effect of glucocorticoids on endothelial 
barriers elsewhere in the body is less well-studied. Here we investigated glucocorticoid-
mediated changes in endothelial flux of Adiponectin (Ad), a hormone with a critical role 
in diabetes. First, we used monolayers of endothelial cells in vitro and found that the 
glucocorticoid dexamethasone increased transendothelial electrical resistance and 
reduced permeability of polyethylene glycol (PEG, molecular weight 4000kDa). 
Dexamethasone reduced flux of Ad from the apical to basolateral side, measured both by 
ELISA and Western blotting. We then examined a diabetic rat model induced by 
treatment with exogenous corticosterone, which was characterized by glucose intolerance 
and hyperinsulinemia 
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Chapter 1: Review of Literature   
 
1.1 Diabetes introduction  
1.1.1 Types of diabetes and their prevalence 
Diabetes mellitus is a chronic disease that is a major global health concern due to 
its increasing prevalence. Statistics generated by the Canadian Diabetes Cost Model 
estimated that diabetes affected approximately 3.4 million Canadians in 2015 (an estimated 
9.3% of Canadian population). Moreover, the model projected an increase to 5 million 
patients by 2025, which accounts for approximately 12.1% of the population. From a 
national survey of individuals aged 20 years and older, nearly 5.7 million individuals 
(22.1% population) are at risk of developing diabetes, and the number is projected to 
increase to 6.4 million (23.2%) by 2025.  
Diabetes has significant impacts on government funding. In 1999, the Canadian 
Diabetes Strategy (CDS) was created with an initial funding of $115 million for 5 years to 
focus on diabetes awareness programs. However, in 2005, the government increased its 
budget by 80% to $18 million per year (Leung, 2016). The budget increase focused on 
expanding public education of diabetes prevention and management of its complications. 
Another diabetes-related policy and program at the federal level focuses on increasing 
awareness of diabetes among the First Nations people, since they are considered as high-
risk communities. The initial funding of $58 million for a period of five years from 1999-
2004 was expanded to $190 million for 2010-2015 (Leung, 2016). The funds mentioned 
above exclude costs that are associated with treatment of long-term complications of 
diabetes. People with diabetes are three times more likely to be hospitalized than those with 
cardiovascular disease, at a 12 times greater risk for end-stage renal disease, and a 20 times 
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greater risk for lower limb amputation when compared to the general population (Booth 
and Cheng, 2013).  
As of late 2015, research from the University of Toronto School of Public Health 
indicated that each diabetic patient costs the healthcare system about $16000 over eight 
years as compared to approximately $6000 for people who do not have diabetes (Rosella 
et al., 2016). Therefore, the expenditure for diabetic care has a significant monetary impact 
on the Canadian health care system. 
1.1.2 Metabolic Syndrome 
Metabolic syndrome (MetS) is a common and complex disorder clustering 
hypertension, obesity, dyslipidemia, and insulin resistance. Diabetes mellitus is the most 
common and widely studied metabolic syndrome. Diabetes mellitus is characterized by an 
alteration in carbohydrate metabolism leading to hyperglycemia with symptoms that 
include polyuria, polydipsia, and weight loss. There are 2 main types of diabetes: type 1 
and type 2 diabetes mellitus. Type 1 diabetes caused by destruction of pancreatic β cells, 
resulting in disrupted and ultimately deficient insulin secretion. Type 2 diabetes is 
characterized by insulin resistance, which is initially compensated for by increased insulin 
secretion but ultimately β cell failure occurs leading to hyperglycemia. In addition to type 
1 and 2 diabetes, gestational diabetes occurs during pregnancy when the body naturally 
becomes more resistant to insulin. Gestational diabetes is not permanent, and blood sugar 
will typically returns to normal after birth. However, gestational diabetes can potentially 
increase the risk of type 2 diabetes in the future.  
Type 2 diabetes is the most prevalent type of diabetes, accounting for nearly 90% of 
the diabetic population worldwide. There are many risk factors for type 2 diabetes 
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including pregnancy, genetics (defects in insulin secretion), age, race, diet, and lack of 
physical activity. However, the best predictor for type 2 diabetes is obesity. The number of 
obese individuals is growing at an alarming rate. From a Canadian government survey of 
the population aged 18 years and older between 2003 and 2014, approximately 8.2 million 
(62%) men and 6.1 million (46%) women had an increased health risk due to excess body 
weight. The number of obese individuals had increased from 57% in men and 41% in 
women prior to the 2003 survey (Shields, 2006). Notably, excessive visceral obesity is 
closely associated with the rising incidence of type 2 diabetes (Ford, 2005; Yusuf et al., 
2005).  
1.2 Diabetes pathophysiology  
1.2.1 Proposed mechanisms responsible for development of diabetes (whole body) 
As mentioned above, obesity is a key risk factor for the emergence of type 2 
diabetes. Adipose tissue regulates glucose metabolism by releasing various adipokines. In 
association with obesity, retinol-binding protein-4 (RBP4) is released and induces insulin 
resistance through reduced phosphatidylinositol-3-OH kinase (PI3K) signalling in muscles 
and enhanced glucose production in the liver by increased expression of the glyconeogenic 
enzyme phosphoenolpyruvate carboxykinase (PEPCK) (Yang et al., 2005). Studies have 
shown an increased release of tumour necrosis factor α (TNF-α), interleukin-6 (IL-6), and 
monocyte chemoattractant protein-1 (MCP-1) from adipose tissue, which suggests 
macrophage infiltration might have a role in the development of insulin resistance (Fain et 
al., 2004; Wellen and Hotamisligil, 2005). Other studies have shown that macrophage 
infiltration into white adipose tissue is increased in association with obesity (Weisberg et 
al., 2003; Xu et al., 2003b). 
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The increase in non-esterified fatty acids (NEFA) levels observed in obesity and 
type 2 diabetes may be responsible for inducing insulin resistance and impairing β-cell 
function (Boden, 1997; Reaven et al., 1988). An increase in NEFA levels causes the 
intracellular accumulation of fatty acid metabolites such as fatty acyl-coenzyme A (fatty 
acyl-coA) and diacylglycerol (DAG), which activate a serine/threonine kinase cascade (e.g. 
protein kinase C) leading to phosphorylation of insulin receptor substrate-1 (IRS-1) and 
insulin receptor substrate-2 (IRS-2), preventing the receptors’ ability to activate 
downstream signaling via PI3K. Hence, downstream insulin-receptor signaling is 
diminished (Shulman, 2000). Previous studies have shown that increased serine/threonine 
phosphorylation of IRS-1 and IRS-2 can significantly reduce their ability to interact with 
the insulin receptor, and impair insulin-induced tyrosine phosphorylation on the receptor 
β-subunit, affecting propagation of insulin signaling in Fao cells (Paz et al., 1997; Paz et 
al., 1996). Furthermore, NEFAs can also bind to the G-protein-coupled receptor GPR40 on 
the cell membrane to activate glucose-stimulated insulin secretion in β-cells, or generate 
fatty acyl-CoA and DAG, which will increase insulin levels through stimulating insulin 
granule exocytosis from β-cells (Itoh et al., 2003; Prentki et al., 2002).  
β-cells are known for their ability to regulate insulin release, which ensures plasma 
glucose concentrations to remain within a healthy range. Increased levels of glucose induce 
insulin release from the secretory granules in the β-cells by increasing intracellular ATP 
(Wilcox, 2005). The adaptive response to insulin resistance involves changes in both 
function and mass of β-cells. Studies have demonstrated that obesity can alter β-cell 
function as well as cell volume. A study using mice fed on a high-fat diet (12 months) to 
induce obesity and insulin resistance has found an increase in islet size rather than new 
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islet formation to accommodate for increased secretory demand (Hull et al., 2005). Human 
studies have also suggested that obese individuals are prone to hypertrophy of existing b-
cells rather than cell proliferation, with volume increasing around 50% (Butler et al., 2003; 
Kloppel et al., 1985).  It has been proposed that activation of the insulin-like growth factor 
1 (IGF-1) receptor leads to phosphorylation of IRS-2, and activation of PI3K/protein 
kinase-B (PKB/Akt) and Ras, leading to the activation of the mitogen-activated protein 
(MAP) kinases ERK-1/2. All of these pathways promote β-cell proliferation, tissue 
regeneration, and survival. In IRS-2 knockout mice, reintroduction of β-cell IRS-2 alone 
can increase β-cell replication and cell mass, hence reversing the diabetic phenotype. 
Therefore, the IGF-1 pathway is important for regulation of β-cell mass (Bernal-Mizrachi 
et al., 2001; Rhodes, 2005; Rui et al., 2001).  
1.2.2 Skeletal muscle and glucose metabolism 
Skeletal muscle has been identified as a major site for insulin-stimulated glucose 
disposal, and hence is a main locus of insulin resistance. Studies have shown that an 
intramuscular triglyceride pool exists within human skeletal muscle as a source of energy 
(Dagenais et al., 1976). Studies utilizing a high fat diet-fed rat model suggested that the 
increase in triglyceride storage within the muscles is clearly associated with impairment in 
insulin-stimulated glucose metabolism, as assessed by euglycemic clamp (Storlien et al., 
1991). They concluded high triglyceride accumulation impaired insulin action.  
 The inability of adipose tissue to store excess energy results in elevated release of 
free fatty acids, causing metabolic dysregulation. The mitochondria have been postulated 
to be key regulators of insulin resistance development. Mitochondria are known for their 
role in energy production; it is the site of oxidative phosphorylation that couples the 
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electron transfer from respiratory substrates to oxygen with ATP synthesis. The respiratory 
chain involves four protein complexes on the inner mitochondrial membrane. Complexes 
I and II transfer electrons to ubiquinone, then to complex III, cytochrome c, complex IV, 
and finally to oxygen (Navarro and Boveris, 2007). There are several theories regarding 
the relationship between mitochondrial dysfunction and insulin resistance. Early studies in 
obese and insulin-resistant individuals have shown a mitochondrial dysfunction phenotype 
(Kelley et al., 1999). One study proposed that the loss of mitochondrial content or function 
resulted in insufficient fatty acid oxidation and excessive lipids in circulation, leading to 
an intracellular accumulation of fatty acyl-coA and DAG in skeletal muscles that interfere 
with insulin signalling (Lowell and Shulman, 2005). Further studies demonstrated that in 
type 2 diabetes patients, skeletal muscles exhibited lower respiratory chain activity due to 
the reduction in the expression of genes encoding mitochondrial enzyme subunits (Kelley 
et al., 2002; Mootha et al., 2003; Patti et al., 2003; Ritov et al., 2010).  
1.2.3 Insulin signalling  
The insulin receptor (IR) is a transmembrane glycoprotein belonging to the receptor 
tyrosine kinases family. It is composed of α- and β- subunits linked by disulfide bonds. The 
α-subunits serve as the extracellular binding site for insulin, whereas the β-subunits contain 
the insulin-regulated tyrosine kinase activity responsible for initiating the signalling 
cascade (Ullrich et al., 1986). The signalling pathway begins with the interaction between 
insulin and the α-subunit of the insulin receptor on the cell surface (Fig. 1). This interaction 
leads to the stimulation of tyrosine kinase activity on the receptor β-subunit. The 
phosphotyrosine-binding (PTB) domain of the insulin receptor substrate (IRS) recognizes 
the activation of IR, subsequently leading to the phosphorylation of tyrosine residues on 
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IRS. Phosphorylated IRS is recognized by the Src homology 2 (SH2) domain on the p85 
regulatory subunit of PI3-kinase, further leading to the activation of PI3K. PI3K facilitates 
the translocation of the insulin-responsive glucose transporter (GLUT4) towards the 
plasma membrane. The link between PI3K and glucose transport is not completely 
understood.  However, several studies suggest that PI3K activation is mediated by the 
recruitment and activation of 3-phosphoinositide-dependent kinases (PDK), and the 
subsequent phosphorylation of serine/threonine kinase (Akt). Akt has several downstream 
substrates including protein kinase C (PKC) and glycogen synthase kinase 3 (GSK3) 
(Bandyopadhyay et al., 1997; Bandyopadhyay et al., 1999). Furthermore, clinical studies 
have demonstrated obesity and type 2 diabetes both exhibit reduced IRS-1 tyrosine 
phosphorylation and reduced PI3K activity by inhibitor kappa B kinase (IKK) and c-Jun 
amino-terminal kinases (JNK) (Aguirre et al., 2000). 
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Figure 1: Insulin signaling pathway in skeletal muscles. The signalling pathway begins 
with the interaction between insulin and the α-subunit of the insulin receptor on the cell 
surface (Fig. 1). The interactions lead to the stimulation of tyrosine kinase activity on the 
receptor β-subunit. The phosphotyrosine-binding (PTB) domain of the insulin receptor 
substrate (IRS) recognizes the activation of IR, subsequently leading to the 
phosphorylation of tyrosine residues on IRS. Phosphorylated IRS is recognized by the Src 
homology 2 (SH2) domain on the p85 regulatory subunit of PI3-kinase, further leading to 
the activation of PI3K. Through a series of additional steps, PI3K facilitates the 
translocation of the insulin-responsive glucose transporter (GLUT4) towards the plasma 
membrane. 
1.3 Glucocorticoids  
1.3.1 Association of glucocorticoids with diabetes 
Glucocorticoid (GC) is a natural hormone secreted by the adrenal cortex under the 
control of the neuroendocrine feedback system for the regulation of circadian rhythms and 
stress. Exposure to GCs in large amounts during treatment for disorders such as Cushing 
syndrome or mental stress induces insulin resistance (Buren and Eriksson, 2005; Ruzzin et 
al., 2005). Skeletal muscles, adipose tissue, and liver were found to be insulin resistant 
after GC treatment (Witchel and DeFranco, 2006) 
1.3.2 GC receptor and control of energy homeostasis 
The glucocorticoid receptor (GR) is crucial for the survival of mice, as GR 
knockout was found to be lethal (Cole et al., 1995). In the absence of a GR-ligand, this 
nuclear receptor stays within the cytosol as part of a multi-protein chaperone complex. 
Upon hormone binding, the GR translocates to the nucleus and binds directly to DNA at 
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glucocorticoid response elements (GREs) on target genes (Schoneveld et al., 2004). The 
concentration of GC in the blood generally rises during stress, fasting, conditions of 
decreased glucose uptake in muscles and fat, or during gluconeogenesis in the liver to 
maintain normal blood glucose levels (Makimura et al., 2003; Munck et al., 1984)  
High levels of glucocorticoid were found in conditions of obesity, hypertension and 
impaired glucose homeostasis (Bjorntorp and Rosmond, 2000; Lemke et al., 2008). In fact, 
an increase in GR activity leads to lower protein and insulin synthesis in skeletal muscles 
(Vegiopoulos and Herzig, 2007). Studies from cultured muscle fibres treated with 
Dexamethasone (Dex) were found to have lower GLUT4 translocation, and reduced 
glycogen synthase activation, leading to the conclusion that Dex diminished glucose uptake 
under insulin-stimulated conditions (Dimitriadis et al., 1997; Weinstein et al., 1998) 
1.3.3 Use of GC as an anti-inflammatory and immunosuppressive drug 
Under normal conditions, GCs have the ability to inhibit inflammatory responses. 
GCs inhibit the vasodilation and vascular permeability that occurs during inflammation, 
and decreases leukocyte accumulation into the inflamed sites. The result is an acute 
reduction in inflammatory events (Perretti and Ahluwalia, 2000). Additionally, in the long 
term, GCs bind to the GR to regulate NF-κB and AP-1 transcription in leukocytes (Ashwell 
et al., 2000), or repress transcription of pro-inflammatory related cytokines, chemokines, 
and cell adhesion molecules that are involved in the initiation of the host inflammatory 
response (Smoak and Cidlowski, 2004).  
1.3.4 Glucocorticoid-induced diabetes models  
Rats injected with Dex were found to have decreased insulin-stimulated Akt 
phosphorylation at both Ser473 and Thr308 sites (Buren et al., 2008). In rat L6 myotubes 
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treated with Dex, a reduction in insulin receptor substrate (IRS-1) protein and PI3K/Akt 
signalling were also observed (Zheng et al., 2010). 
Long term usage of GCs potentially lead to adverse side effects such as osteoporosis, 
chronic interstitial nephritis, retinopathy, and diabetes (Kessing et al., 2010; Perneger et 
al., 1994; Wolfe and Marmor, 2010; Yang et al., 2006). In senior patients, the risk of 
diabetes doubled after 1 year of exposure to GCs  (Blackburn et al., 2002). Moreover, 38% 
of young people who are chronically treated with steroids have undergone regular 
monitoring for diabetes (Blackburn et al., 2002) (Panthakalam et al., 2004).  
 
1.4 Iron and diabetes risk  
1.4.1 Association between iron and metabolic syndrome 
The connection between iron and metabolism is well established. To examine the 
link between iron and diabetes, a group of researchers generated human hemochromatosis 
protein knockout (HFE KO) mice, which exhibited impaired glucose-stimulated insulin 
secretion and increased β-cell apoptosis (Cooksey et al., 2004). The crosstalk between iron 
metabolism and diabetes has also been demonstrated by Tanner and Lienhard, who 
observed co-localization of transferrin receptors and glucose transporters on the membrane 
of adipocytes in vitro. Their study suggested that the regulation of iron occurs in parallel 
with its effects on glucose transport (Tanner and Lienhard, 1989). Increased iron storage is 
associated with the development of type 2 diabetes (Fernandez-Real et al., 2002). Ferritin 
is one of the key proteins regulating iron homeostasis and it is a widely used clinical 
biomarker of iron status. Clinical studies have shown that higher serum ferritin levels were 
found in patients with metabolic syndrome and insulin resistance. Thus, high iron level is 
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associated with increased risk of type 2 diabetes, suggesting it may be a prevalent cause of 
diabetes (Moreno et al., 2015) 
Thalassemia is a disorder characterized by a deficiency in the β-globin subunit of 
hemoglobin. Patients become overloaded with iron from increased iron absorption, because 
the patients’ body is unable to maintain normal erythrocyte levels in the blood to uptake 
the iron that is taken up by the gut (Weatherall, 1998). Clinical studies on thalassemia have 
also found that these patients have insulin deficiency and resistance, which may lead to a 
prediabetic state and the development of diabetes (Messina et al., 2002).  
1.4.2 Iron homeostasis 
Serum and tissue iron levels are regulated by hepcidin. Hepcidin promotes 
internalization and ubiquitin-mediated degradation of ferroportin (FPN), an iron exporter. 
Hepcidin therefore inhibits iron release and reduces circulating iron levels, but accumulates 
iron in tissues. The main source of iron for most cells is through the uptake of transfferin 
(Tf)-bound iron and its receptor (TfR1). Tf is a protein produced by the liver that binds to 
iron molecules. Tf enters and is redistributed to the cells via TfR1, which is internalized 
through clatherin-mediated endocytosis. The circulating ferric form of iron is released, and 
the Tf-TfR1 complex is recycled back to the cell membrane where the complex is 
separated. Hepcidin is not normally involved in the regulation of iron release unless Tf is 
saturated, leading to the formation of non Tf-bound iron (NTBI). When Tf is saturated and 
NTBI is formed, the free cellular iron is toxic and redox-active.  
1.4.3 Iron overload in humans (e.g., Hereditary hemochromatosis) 
Although type 2 diabetes is largely attributed to the obesity epidemic, the 
underlying genetic cause of this metabolic syndrome is unknown. Hereditary 
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hemochromatosis (HH) is an autosomal recessive disorder characterized by excess iron 
concentration in the body. The most common form of this disease is caused by a mutation 
in the HFE gene resulting in a C282Y substitution in the HFE protein. The HFE protein is 
responsible for iron metabolism by acting as an iron sensor for the body to regulate iron 
absorption in the small intestine, and the recycling of iron by macrophages (Feder et al., 
1996). While HFE normally functions through the stimulation of hepcidin, a mutation in 
HFE causes a decline in hepcidin expression, resulting a higher than normal iron absorption 
(Nemeth et al., 2004). Mutation in HFE was thought to be an adaptive response in 
populations with an iron-deficient diet (Toomajian et al., 2003). Clinical studies have 
demonstrated HH patients cannot respond to increased insulin secretion demand primarily 
due to the β -cell pathology. In these patients, insulin sensitivity will improve after 
phlebotomy therapy to achieve iron depletion. Hence, these patients are at a higher risk to 
develop diabetes (Abraham et al., 2006; McClain et al., 2006).  
1.4.4 Iron overload – animal models 
An alteration in iron homeostasis allows uncontrolled iron entry to different organs, 
progressively leading to tissue damage and organ failure. To study this phenomenon, many 
laboratories have created a genetic knockout model of hemojuvelin (HJV), a membrane 
protein that acts as a co-receptor in the SMAD pathway to regulate hepcidin expression. 
Hepcidin is a key regulator of iron metabolism that works by binding to the iron export 
channel ferroportin, the resulting inhibition of iron transport results in an iron overload. 
Iron accumulation and morphological damage of the retina has been shown in mice with 
HJV deletion (Gnana-Prakasam et al., 2012). Moreover, a murine iron overload model was 
achieved by HJV deletion in combination with dietary iron supplement and iron injection. 
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It increased oxidative stress and myocardial fibrosis, resulting in heart disease (Das et al., 
2015).  
1.4.5 Iron overload and glucose metabolism 
The liver is the major site of iron storage in the body as transferrin-bound iron is 
taken up by hepatocytes via TfR1. When excess iron is stored in the liver it interferes with 
glucose metabolism and causes hyperinsulinemia (Niederau et al., 1984). Insulin enhances 
the uptake of extracellular iron by inducing expression of TfRs at the cell surface, as well 
as down regulating the expression of hepcidin (Davis et al., 1986; Wang et al., 2014).  
1.4.6 Physiological effects of iron 
Iron is an essential nutrient that plays an important role as a cofactor for fuel 
oxidation and electron transport, as well as being required for normal cellular structure and 
functions such as cell growth and proliferation (Gozzelino and Arosio, 2016).  However, 
excessive amounts of iron could be toxic if not carefully regulated. Iron, combined with 
Hydrogen Peroxide (H2O2), generates various Reactive Oxygen Species (ROS) through the 
Fenton reaction. This process causes oxidation of organic pollutants such as pesticides 
(Mirzaei et al., 2017). In rodent models, changes in iron homeostasis led to uncontrolled 
iron entry and deposition in skeletal muscles, and progressively caused insulin resistance, 
a key contributor to diabetes (Huang et al., 2011) 
1.4.7 Cellular effects of iron 
Oxidative stress has long been known to be a major causal factor for diabetes and its 
complications. For example, elevated ROS reduced metabolite clearance in patients with 
chronic renal failure (Toborek et al., 1992). Free radicals also disrupt tight junction (TJ) 
function by altering the cell-cell adherence properties of TJ proteins, and by inducing 
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reorganization of the actin filament network (Wichmann et al., 2015; Won et al., 2011). 
Another study suggested that iron overload in mice led to elevated ROS. Interestingly, iron 
overload was associated with decreased levels of TJ structural proteins occludin and zonula 
occludens 1 (ZO-1), and hence caused a disruption in TJ structure, resulting in increased 
permeability of hippocampal endothelial cells isolated from TFI-induced iron overloaded 
rats. Endothelial dysfunction contributes to the pathogenesis of atherosclerosis in diabetes 
(Handa et al., 2016; Won et al., 2011). Furthermore, previous research has found that 
inflammation coexisting with increased oxidative stress occurs in end-stage renal disease 
(Raj et al., 2005). ROS enters human skeletal muscles and activates an inflammatory 
cascade via activation of nuclear factor-kB (NF-κB), as well as upregulation of expression 
of various cytokines, including interleukin- 6 and 10 (IL- 6, 10) and TNF-α, in response to 
stimuli. The impaired glucose tolerance is associated with increased serum concentrations 
of these cytokines (Muller et al., 2002) 
1.5 Adiponectin  
1.5.1 Association of adiponectin with diabetes 
The adipose tissue is an endocrine organ that secretes various adipokines to mediate 
metabolic effects (Valencak et al., 2017). Adiponectin (Ad) is one such adipokine, and its 
gene is located on a chromosome that has been identified as a diabetes-susceptible locus in 
genome-wide association studies (Mori et al., 2002; Vionnet et al., 2000). Hence, it is 
theorized to be a diabetes-related hormone. Ad is a 30kD protein that is primarily secreted 
by adipocytes and circulates abundantly in the blood stream at 3-30 µg/ml. The adiponectin 
protein must undergo post-translational modification before being secreted into the 
circulation (Dadson et al., 2011). Ad can exist as a full-length protein, or as a globular 
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fragment. The monomers can form trimers (low molecular weight (LMW) form), hexamers 
(medium molecular weight (MMW) form), and higher order oligomers (high molecular 
weight (HMW) form). The mixture of these different oligomeric forms is termed full length 
Ad (fAd). The globular form of Ad is generated during the posttranslational modification 
of fAd, and is smaller, consisting of the carboxyl-terminal domain, but it can also mediate 
biological effects (Dadson et al., 2011).  
Many studies have recognized the role that a reduction in adiponectin action has in 
the metabolic syndrome and obesity-related diseases. The level of circulating adiponectin 
has an inverse relationship with BMI, plasma glucose, and serum triglycerides (Ouchi et 
al., 2011), and it is significantly reduced in obese/diabetic mice and humans (Hu et al., 
1996; Yamauchi et al., 2001). Furthermore, Ad mRNA expression is down regulated in 
db/db obese diabetic mice (Hu et al., 1996). Thus, a reduction in circulating adiponectin 
levels is consistently observed in conditions associated with insulin resistance. Two main 
mechanisms that have been proposed for impaired adiponectin action in tissues are: 1) 
decrease circulating levels of adiponectin, or 2) reduced adiponectin sensitivity, both of 
which may promote inflammation in obesity and diabetic conditions, as adiponectin has 
potent anti-inflammatory effects (Yamauchi and Kadowaki, 2013).  
1.5.2 Regulation of adiponectin production 
Adiponectin is the product of the APM1 gene, which has been mapped to the human 
chromosome 3q27 locus, a diabetes-susceptible site. The gene is under transcriptional 
regulation by peroxisome proliferator activated receptor γ (PPARγ). It is a ligand-activated 
transcription factor belonging to the nuclear family of receptors. PPARγ deletion in mice 
reduces circulating adiponectin levels, hence diminishing adiponectin’s antidiabetic and 
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cardioprotective effects. An increase in PPARγ activity increases adiponectin levels in the 
circulation. The most well-known and commonly used anti-diabetic drugs, such as 
rosiglitazone, belong to the thiazolidinedione (TZD) class of drugs. These drugs work to 
enhance insulin sensitivity and lower blood glucose levels by increasing adiponectin levels 
through PPARγ activation (Maeda et al., 2001). In contrast to PPARγ, cAMP response 
element-binding protein (CREB) has been identified as a repressor of adiponectin gene 
expression. This transcription factor is indirectly responsible for hyperglycemia and insulin 
resistance by down regulation of adiponectin through upregulation of ATF3, a gene 
repressor. (Kim et al., 2006). TNF-α is a pro-inflammatory cytokine that is known to 
suppress upstream adiponectin signalling through inhibition of PPARγ, and preventing SP-
1 promotor binding, hence decreasing gene expression as well as reducing signalling 
cascades (Park et al., 2008).  
1.5.3 Adiponectin signalling 
The adiponectin signalling cascade is initiated by the interaction of circulating 
adiponectin with its transmembrane adiponectin receptor isoforms AdipoR1/R2. The 
receptors have seven transmembrane domains with an intracellular N-terminus and an 
extracellular C-terminus (Lee et al., 2008). It has been suggested that these receptors get 
phosphorylated at the tyrosine site and undergo conformational changes to initiate the 
signalling cascade. AdipoR1 is most abundant in the skeletal muscles and has a higher 
affinity for gAd as compared to fAd. The liver mainly expresses AdipoR2. Adaptor protein 
phosphotyrosine interacting with PH domain and leucine zippers 1 (APPL1) is an adaptor 
protein that interacts with the N-terminal intracellular domain of AdipoR1/R2 through its 
PTB domain (Lee et al., 2011). APPL1 has been shown to interact with the p110 catalytic 
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subunit and p85 regulatory subunit of PI3K, and also with Akt (Backer, 2010). Hence, 
APPL1 is a key adaptor protein responsible for the crosstalk between adiponectin and the 
insulin signalling pathway. Translocation of the glucose transporter GLUT4 to the cell 
surface was diminished in APPL1 knockdown in a skeletal muscle cell model (Dadson et 
al., 2011). Other than its role in mediating the insulin-sensitizing effects of adiponectin, 
the signalling cascades activated by APPL1 are also known for roles in cell proliferation, 
chromatin remodeling, and cell survival (Liu et al., 2017)  
AMP-activated protein kinase (AMPK) is a downstream target of AdipoR/APPL1 
signalling. AMPK belongs to the family of energy sensing enzymes that are activated by 
ATP depletion. Fatty acid uptake and oxidation is the primary energy source for cardiac 
cells, a process which is upregulated by Ad. Conversely, Ad also suppresses fatty acid 
synthesis through the activation of AMPK, p38 MAPK and PPARα. AMPK 
phosphorylation is critical for the activation of palmitoytransferase-1 (CPT-1), a 
mitochondrial outer membrane protein responsible for transporting long chain fatty acids 
(LCFAs) into the mitochondria. In its dephosphorylated and activated state, acetyl CoA 
carboxylase (ACC) produces malonyl-CoA, which inhibits CPT-1 activity and prevents the 
mitochondrial import of LCFAs. However, AMPK phosphorylates and deactivates ACC 
and releases the inhibition of CPT-1, allowing LCFAs to be transported into the 
mitochondria for oxidation (Yoon et al., 2006). 
PPARα (a ligand-activated nuclear hormone receptor) controls the expression of a 
number of genes involved in mitochondrial β-oxidation such ACO, CPT1, and FABP3 for 
the generation of energy from fatty acid oxidation in the liver, heart, kidney, and skeletal 
muscles (Rodriguez et al., 1994). Studies using PPARα knockout mice have demonstrated 
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defects in fatty acid oxidation, resulting in elevated plasma free fatty acid levels and 
hypothermia (Hashimoto et al., 2000; Kersten et al., 1999).  
p38 mitogen-activated protein kinase p38 MAPK is activated by inflammatory 
cytokines and has an important role in initiating an immune response upon metabolic stress 
(e.g. muscle contraction, ischemia). These physiological conditions are similar to those 
associated with AMPK activation, suggesting possible crosstalk between the AMPK and 
p38 MAPK signalling pathways (Hayashi et al., 2000). 
1.5.4 Physiological effects of adiponectin 
The physiological significance of Ad as an insulin-sensitizing adipokine is well 
established. Although adipocytes are the main source of circulating Ad, several studies 
have now demonstrated the potential for Ad production by skeletal muscles (Liu et al., 
2009). Since skeletal muscle is the main site for glucose disposal in the body, it makes 
sense for it to be an important peripheral target tissue for Ad to exert its metabolic effects, 
and indeed has proved to be a site of Ad’s anti-diabetic action. Cultured mouse and rat 
skeletal muscle cells demonstrate enhanced glucose uptake with Ad treatment (Ceddia et 
al., 2005; Yamauchi et al., 2002). Furthermore, administration of Ad to ob/ob mice was 
shown to reverse hyperglycemia (Xu et al., 2003a)  
1.6 Transport of hormones across vascular endothelium  
1.6.1 Structure and function of vascular endothelium 
A monolayer of endothelial cells lines the entire circulatory system of the body. 
This endothelium acts as a barrier which regulates the exchange of hormones, proteins, and 
small molecules between the vascular compartment and the interstitial space (Goddard and 
Iruela-Arispe, 2013; Pries and Kuebler, 2006). The actions of a hormone or nutrient on a 
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target tissue are implicitly dependent upon the ability of these factors to gain access to the 
target. Numerous studies have indicated that hormone and nutrient concentrations in blood 
differ from those surrounding cells on the tissue side of the blood vessel endothelium 
(Barrett et al., 2011; Bodenlenz et al., 2005; Chiu et al., 2009; Chiu et al., 2008; Herkner 
et al., 2003; Kolka et al., 2010; Maggs et al., 1995; Sjostrand et al., 1999; Yang et al., 
1994). In this regard, it is our contention that the significance of the endothelium as a 
regulator of hormone and substrate access to target tissues is often underappreciated. Two 
distinct pathways can regulate endothelial permeability: 1) the transcellular pathway, 
where solutes are actively transported across the endothelium, primarily via caveolae-
mediated transcytosis; or 2) the paracellular pathway, where solutes passively move 
through the intercellular space between adjacent endothelial cells. 
1.6.2 Transcellular and paracellular transport  
The transcellular movement of solutes involves energy-dependent trafficking of 
vesicles across the endothelium (Goddard and Iruela-Arispe, 2013). This often requires 
their recognition by receptors in caveolae on the luminal surface of the endothelium, 
though it may also involve vesiculo-vacuolar organelles, or occur via transcellular channels 
(Goddard and Iruela-Arispe, 2013). Caveolae are cholesterol- and sphingolipid-rich non-
clathrin-coated pits, and are abundant in endothelial cells. After ligand binding to receptors 
in caveolae, dynamin-mediated endocytosis occurs, followed by vectorial transport and 
fusion of the vesicle with the basolateral plasma membrane, resulting in the release of 
contents by exocytosis (Goddard and Iruela-Arispe, 2013). As a general concept, 
transcellular vesicle trafficking is important in the transport of larger macromolecules 
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across the endothelium, since the paracellular route is typically restricted to passaging of 
solutes smaller than 3 nm in radius (Gunzel and Fromm, 2012; Gunzel and Yu, 2013). 
The paracellular mode of transport across the endothelium depends upon 
concentration gradients between blood and interstitial fluid. One regulatory mechanism of 
paracellular movement involves tight junctions (TJs), which are composed of strands of 
transmembrane and cytosolic proteins that closely control paracellular flux and have been 
established to be important in regulating hormone transport (Gunzel and Yu, 2013; Kolka 
and Bergman, 2012; Kolka et al., 2010). As a component of the cell-cell junctions between 
endothelia, TJs provide a selective barrier to solute movement between cells (Gunzel and 
Fromm, 2012). The perm-selectivity of the TJ barrier is dependent on the variable 
assemblage of TJ proteins that comprise the complex. Proteins such as occludin, tricellulin, 
and claudins directly establish the TJ barrier and form the backbone of TJ strands while 
the cytosolic proteins, such as ZO-1, provide structural support to the TJ complex. The 
incorporation of specific TJ protein isoforms can enhance TJ barrier function (i.e., make 
TJs tighter) or form channels to increase TJ permeability (i.e., make TJs leakier) (Gunzel 
and Fromm, 2012). Importantly, skeletal muscle and heart vasculature have continuous 
endothelium with TJs between cells (Aird, 2007a, b). However, the liver and spleen have 
a discontinuous endothelium with large holes, which allow rapid equilibration of plasma 
with the underlying tissue (Aird, 2007a, b). It was suggested that this expedited exposure 
of the liver to plasma solute changes, due to its characteristic fenestrated endothelium, may 
partly explain its earlier susceptibility to insulin resistance (Braet and Wisse, 2002; Kim et 
al., 2003).  
1.6.3 Endothelial dysfunction in diabetes 
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Impaired vascular endothelial function is an early marker for atherosclerosis, which 
causes cardiovascular complications. The concept of endothelial dysfunction in diabetes is 
well established (Ding and Triggle, 2010). However, this typically refers to vascular 
functions independent of transendothelial solute flux. The endothelium is also a dynamic 
interface that responds to various stimuli, and synthesizes and liberates vasoactive 
molecules such as nitric oxide, prostaglandins and endothelin. Accordingly, vascular 
complications in diabetes include outcomes occurring in large (atherosclerosis, 
cardiomyopathy) and small (retinopathy, nephropathy, neuropathy) vessels (Symons and 
Abel, 2013). We believe that diabetes-induced deleterious alterations in paracellular solute 
movement also represent a form of endothelial dysfunction which should be fully 
characterized to establish its physiological significance. 
1.7 Research	objectives/	hypothesis	&	specific	aims		
	
As described above, regulation of the permeability of the endothelial barrier is an 
important way in which hormone access to the target tissue is controlled. I hypothesized 
that targeting tight junctions to alter endothelial permeability could control adiponectin 
flux, and consequently its cellular and physiological functions. To test this hypothesis, the 
following objectives were established: 
Objective 1: Test whether using glucocorticoids to increase tightness of endothelial tight 
junctions could restrict adiponectin flux and action. 
Aim 1: Use the synthetic glucocorticoid Dex to modify Human Umbilical Vein Endothelial 
Cells (HUVEC) tightness and test for changes in permeability of adiponectin.  
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Aim 2: Test mechanisms underlying changes observed in Aim 1: examine changes in 
endothelial tight junction components using Western blot and mRNA. Examine 
adiponectin flux in HUVEC where claudin-7 expression was reduced using shRNA. 
Aim 3: Determine the effect of glucocorticoid Corticosterone (Cort) on the expression of 
adiponectin, its receptors, and tight junction components in rats treated with Cort. 
Objective 2: Investigate whether iron could change endothelium tightness and alter 
metabolism  
Aim 1: Test whether iron directly modifies Human Dermal Microvascular Endothelial Cell 
(HDMEC) permeability and adiponectin flux.  
Aim 2: Using a mouse model of iron overload, test whether insulin sensitivity and glucose 
clearance was altered.  
Aim 3: Determine tissue-specific effects and molecular mechanisms responsible for 
changes in glucose metabolism and activity using comprehensive lab animal monitoring 
system and western blotting.  
	 23	
Statement of Contribution 
Chapter 2: T. Dang contributed to planning and conducting experiments, except for the 
[3H]PEG-4000 and real-time PCR experiments performed by H. Chasiotis. Samples from 
the animal model of diabetes induced by exogenous corticosterone were obtained from E. 
Dunford. This chapter was co-written by H. Chasiotis, edited by Dr. G. Sweeney, and is 
published in the Journal of Endocrinology. 
Chapter 2: Study 1 
Transendothelial movement of adiponectin is restricted by glucocorticoids 
1.1 Abstract  
Altered permeability of the endothelial barrier in a variety of tissues has implications 
both in disease pathogenesis and treatment. Glucocorticoids are potent mediators of 
endothelial permeability and this forms the basis for their heavily-prescribed use as 
medications to treat ocular disease. However, the effect of glucocorticoids on endothelial 
barriers elsewhere in the body is less well-studied. Here we investigated glucocorticoid-
mediated changes in endothelial flux of Adiponectin (Ad), a hormone with a critical role 
in diabetes. First, we used monolayers of endothelial cells in vitro and found that the 
glucocorticoid dexamethasone increased transendothelial electrical resistance and reduced 
permeability of polyethylene glycol (PEG, molecular weight 4000kDa). Dexamethasone 
reduced flux of Ad from the apical to basolateral side, measured both by ELISA and 
Western blotting. We then examined a diabetic rat model induced by treatment with 
exogenous corticosterone, which was characterized by glucose intolerance and 
hyperinsulinemia. There was no change in circulating Ad but less Ad protein in skeletal 
muscle homogenates, despite slightly higher mRNA levels, in diabetic versus control 
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muscles. Dexamethasone-induced changes in Ad flux across endothelial monolayers were 
associated with alterations in the abundance of select claudin (CLDN) tight junction (TJ) 
proteins. shRNA-mediated knockdown of one such gene, claudin-7, in HUVEC resulted 
in decreased TEER and increased adiponectin flux, confirming the functional significance 
of Dex-induced changes in its expression. In conclusion, our study identifies 
glucocorticoid-mediated reductions in flux of Ad across endothelial monolayers in vivo 
and in vitro. This suggests that impaired Ad action in target tissues, as a consequence of 
reduced transendothelial flux, may contribute to the glucocorticoid-induced diabetic 
phenotype. 
1.2 Introduction	
 As the primary barrier to the movement of circulating endocrine factors from the 
bloodstream to the interstitial space, the endothelium plays a critical role in hormone action 
(Kolka and Bergman, 2012; Yoon et al., 2014). Endothelial permeability can significantly 
impact hormone action by preventing or delaying access of the hormone to target tissues 
(Kolka and Bergman, 2012; Won et al., 2011). Transendothelial solute movement can 
occur via the transcellular pathway where solutes are transported across the endothelium 
cell membrane or via the paracellular pathway where solutes passively move through the 
intercellular space between adjacent endothelial cells (Yoon et al., 2014) .Previous work 
has shown that hormone and nutrient concentrations in blood differ from surrounding cells 
on the tissue side of the blood vessel endothelium (Barrett et al., 2011; Herkner et al., 2003; 
Yang et al., 1994).Of note, this has been best documented in the case of insulin where 
concentrations of the hormone are significantly lower in the target tissue than in the 
circulation (Kolka and Bergman, 2012). 
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 Glucocorticoids are among the most commonly prescribed anti-inflammatory and 
immunosuppressive medications worldwide (Clark and Belvisi, 2012). They are also 
commonly used in oncology treatment (Lin and Wang, 2016) and for the treatment of 
macular edema and, more recently, retinopathy (Agarwal et al., 2015; Zhang et al., 2014). 
However, glucocorticoids have been shown to have potent effects on restricting endothelial 
transport (Felinski and Antonetti, 2005; Witt and Sandoval, 2014) and they contribute to 
the development of diabetes at least in part by increasing hepatic glucose production and 
reducing GLUT4 translocation in muscle (Beaudry et al., 2015) . Yet despite these 
observations, the potential importance of glucocorticoid-induced alterations in the 
transendothelial flux of circulating glucoregulatory hormones such as Ad is unclear. 
 Ad is one of the most abundant plasma proteins and exists in three different 
isoforms: low molecular weight (LMW; trimer), medium molecular weight (MMW; 
hexamer) and high molecular weight (HMW; oligomer) (Dadson et al., 2011). Ad has 
important and beneficial anti-diabetic, anti-inflammatory and cardioprotective actions 
(Arita et al., 2002; Dadson et al., 2011). Ad levels, in particular HMW, are decreased in 
obese individuals and this correlates with development of associated complications, 
including diabetes and cardiovascular disease (Kadowaki et al., 2006; Peters et al., 2013). 
Transendothelial movement of Ad across the blood-brain barrier (BBB) into cerebrospinal 
fluid (CSF) was studied and only LMW and MMW were found in the CSF, suggesting that 
passage of HMW complexes were restricted (Kubota et al., 2007; Kusminski et al., 2007; 
Neumeier et al., 2007). This may be functionally significant since HMW Ad is often 
considered to be the most biologically active and physiologically relevant form (Dadson et 
al., 2011; Nanayakkara et al., 2012). A recent study calculated the Stokes radii for the Ad 
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oligomers and found that endothelial barriers controlled Ad transport in a cell- and tissue-
specific manner (Rutkowski et al., 2014). Thus, emerging evidence suggests that Ad action 
may be at least in part mediated by endothelial transport, although whether this is 
influenced by glucocorticoid-induced changes in transendothelial permeability remains 
unknown. 
 Given the large size of Ad multimers it seem likely that transendothelial Ad 
movement is an important variable in determining it presence within, and action on, target 
tissues. Therefore we hypothesized that glucocorticoid-induced alterations in 
transendothelial permeability will modulate the transendothelial movement of Ad. In this 
regard, the objective of this study was to examine how glucocorticoid treatment of a 
cultured endothelium influences Ad flux in association with changes in permeability and 
apical junction protein abundance as well as investigate Ad content within the skeletal 
muscle in a diabetic rat model induced by exogenous glucocorticoid treatment. The overall 
goal of this work was to significantly advance our understanding of the glucocorticoid-
induced diabetic phenotype by determining whether Ad movement out of the circulatory 
system might play a role in its pathogenesis. 
1.3 Material	and	Methods	
	
1.3.1 HUVEC cell culture and treatments 
Normal primary human umbilical vein endothelial cells (HUVECs; Pooled, PCS-100-
013) were obtained from ATCC (Manassas, VA, USA) and grown at 37°C and 5% CO2 on 
uncoated T75 flasks in vascular cell basal medium (ATCC, PCS-100-030) containing 10% 
fetal bovine serum (FBS), VEGF endothelial cell growth kit (ATCC, PCS-100-041) and 
treated with DEX using 2% FBS (both medium were prepared without hydrocortisone 
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hemisuccinate), 100 units/mL penicillin and 100 µg/mL streptomycin. Cells were kept 
frozen in medium containing 10% DMSO (Bio-Rad Laboratories Canada Ltd., 
Mississauga, ON, Canada). For experiments, passage 3 was used. Cells were counted using 
a haemocytometer and seeded onto permeable polyethylene terephthalate (PET) filters at 
the base of BD Falcon cell culture inserts (BD Biosciences, Mississauga, ON, Canada) at 
a density of 0.5 x 106 cells/insert.  
Dexamethasone (DEX) was obtained from Sigma-Aldrich (Oakville, ON, Canada), and 
full-length Ad was produced in-house using a mammalian expression system (i.e. HEK 
293 cells) according to methods described by (Wang et al., 2002; Xu et al., 2004). HUVECs 
were treated for 5 days with DEX (1 µM) starting 24 h after seeding cells into inserts, 
HUVECs were treated with DEX added to both apical and basolateral sides of inserts at 
concentrations indicated above 
1.3.2 shRNA-mediated knockdown of claudin-7 in HUVEC 
We used pGPU6/Neo-claudin-7 shRNA vector with target sequence (5’- 
GGCCATCAGATTGTCACAGAC-3’) (GenePharma Co., Ltd., Shanghai, China). These 
were transfected into HUVEC using LipofectamineTM 3000 Reagent (Invitrogen, Carlsbad, 
CA, USA) exactly according to manufacturer’s protocol. Non-specific scrambed target 
sequence shRNA vector was used as control. Following selection with 50 ug/ml Neomycin 
(Sigma-Aldrich, Oakville, ON, CA) for 24 hours, cells were seeded onto inserts for analysis 
of TEER, examining adiponectin flux or preparation of cell lysates to confirm claudin-7 
knock-down.  
2.3.3 Transendothelial electrical resistance (TEER),and [3H]PEG4000 and Adflux 
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TEER was measured daily using chopstick electrodes (STX-2) connected to an EVOM 
voltohmmeter (World Precision Instruments, Sarasota, FL, USA). As a measure of 
paracellular permeability, apical to basolateral flux rates of [3H] polyethylene glycol at 1 
µCi; 1 h flux(molecular mass 4000 Da; PEG-4000; PerkinElmer, Woodbridge, ON, 
Canada)or Ad (10 µg/mL; 24 h flux) to apical culture medium were determined across 
HUVEC endothelia. [3H]PEG-4000 in basolateral culture medium was detected using a 
liquid scintillation counter, Ad was detected using a mouse Ad ELISA kit (Antibody 
Immunoassay Services, Hong Kong) or Western blot. Permeability measurements were 
expressed according to calculations previously outlined by (Wood et al., 1998). 
2.3.4 Quantitative real-time PCR analysis 
Total RNA was isolated from control and DEX-treated HUVECs and from soleus 
skeletal muscle using TRIzol Reagent . Extracted RNA was then treated with DNase I and 
first-strand cDNA was synthesized using SuperScript III reverse transcriptase and 
oligo(dT)12-18 primers (Life Technologies Inc.,Manassas MA, USA). Quantitative real-time 
PCR (qRT-PCR) analyses were conducted using gene specific primers. SYBR Green I 
Supermix (Bio-Rad Laboratories Canada Ltd.Mississauga, ON, Canada) and a Chromo4 
Detection System (CFB-3240; Bio-Rad Laboratories Canada Ltd.) Samples were run in 
duplicate. For all qRT-PCR analyses, TJ protein mRNA expression was normalized to 
GAPDH transcript abundance. For the expression profile, TJ protein transcripts were 
expressed relative to occludin mRNA. For TJ protein transcripts that were not detected in 
HUVECs, normal human adult kidney cDNA was obtained (BioChain Institute, Inc., 
Newark, CA, USA) and used as a positive control in qRT-PCR reactions. Agarose gel 
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electrophoresis verified single qRT-PCR products at predicted amplicon sizes from 
positive control reactions. 
2.3.5 Animal model of diabetes induced by exogenous corticosterone treatment 
We used a well-established hyperinsulinemic/hyperglycemic rodent model of chronic 
glucocorticoid treatment (Beaudry et al., 2013; Beaudry et al., 2015; D'Souza A et al., 
2012; Shikatani et al., 2012; Shpilberg et al., 2012). Upon experiment cessation, the tibialis 
anterior (TA) and soleus skeletal muscles were excised and immediately frozen in liquid 
N2 and kept at -80oC until future analysis. 
2.3.6 Measurement of hydraulic conductivity (Lp) in individually perfused rat mesenteric 
microvessel 
Female Sprague-Dawley rats of 220 to 250 g (2 to 3 mo old, Sage Laboratory Animal, 
PA) were used for the experiments. All procedures and animal use were approved by the 
Animal Care and Use Committee at Pennsylvania State University. Inactin hydrate (Sigma) 
was used for anesthesia and given subcutaneously at 170 mg/kg body weight. Microvessel 
permeability was assessed by measuring Lp in individually perfused microvessels, which 
measures the volume of water flux across the microvessel wall. Details have been described 
previously (Yuan and He, 2012; Yuan et al., 2014).  
2.3.7 Immunohistochemistry of Ad and dystrophin in skeletal muscle 
Tibialis anterior (TA) from Control and CORT treated rats were cryostat sectioned (10 
µm thick) for analysis of muscle Ad content. Sections were stained as previously described 
(Krause et al., 2008). Quantification was performed using Zen 2.0 software. The total Ad 
and dystrophin signal was determined bythe sum of red/green signal intensity obtained 
arbitrary values in the field of view. Diagram view intensity was recorded by the software 
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in form of histograms. Intracellular quantification was done on Ad images (without 
dystrophin), images were changed to 8-bits on Image and the arbitrary intensity was 
calculated as mean intensity per area. 
2.3.8 Western blot analysis 
Control and DEX-treated HUVECs, and L6 or H9C2 cells treated with HUVEC-
conditioned medium and soleus skeletal muscle were lysed in sample buffer (80 mMTris-
HCl (pH 6.8), 2% (w/v) SDS, 20% glycerol, 3.3% (v/v) β-mercaptoethanol 0.01% w/v 
bromophenol blue) containing protease and phosphatase inhibitors (3 mM EDTA, 10 uM 
E64, 1 mM Na3VO4, 1 µM leupeptin, 1 µM pepstatin A, 1 µM okadaic acid and 200 µM 
PMSF). Apical and basolateral HUVEC-conditioned media collected from Ad flux 
experiments were concentrated with Amicon Ultra-4 Centrifugal Filter Units with Ultracel-
30 membranes (EMD Millipore, Billerica, MA, USA) and subjected to nondenaturing, 
nonreducing conditions to allow the analysis of the different forms of Ad (HMW >250 
kDa, MMW ~180 kDa, and LMW ~90 kDa). Primary antibodies specific for the following 
proteins: T-cadherin (1:1000, R&D Systems), occludin (OCLN, 1:3000), tricellulin (TRIC, 
1:3000), claudin-7 (CLDN-7, 1:500), CLDN-10 (1:800), CLDN-11 (1:1000), phospho-
AMPKα (Thr172) (1:1000), phospho-p38 MAPK [pT180/pY182] (1:1000), Ad 
(1:1000),β-actin (1:1000). OCLN, TRIC, CLDN-7, CLDN-10 and phospho-p38 MAPK 
[pT180/pY182] antibodies were obtained from Life Technologies, CLDN-11 and Ad 
antibodies were purchased from EMD Millipore and Signalway Antibody (College Park, 
MD, USA) respectively, and phospho-AMPKα (Thr172) and β-actin antibodies were 
obtained from Cell Signaling Technology (New England Biolabs Ltd., Whitby, ON, CA). 
Protein detection using enhanced chemiluminescence (Bio-Rad) and quantification by 
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densitometry using ImageJ analysis software. TJ protein expression was normalized to β-
actin, Tubulin protein abundance. 
2.3.9 Statistical analysis 
All data are expressed as mean values ± SEM. A one-way analysis of variance 
(ANOVA) followed by a Student-Newman-Keuls test was used to determine significant 
differences (P ≤ 0.05) between groups. When appropriate, a Student’s t-test was also used. 
All statistical analyses were conducted using Prism 5, Excel SigmaStat 3.5 softwares.  
2.4 Results 
 
2.4.1 Dexamethasone induces endothelial tightening and inhibits Ad movement across 
endothelial cell monolayers 
We first investigated the effect of dexamethasone (DEX), a synthetic glucocorticoid, on 
tightness of an endothelial monolayer of HUVECs. Addition of DEX to culture media 
significantly elevated TEER (Fig. 1A) and correspondingly reduced the endothelial 
permeability of the paracellular transport marker [3H]PEG-4000 (Fig. 1B). Similar trends 
regarding permeability were observed in microvessels of DEX-treated rats. DEX treatment 
(n = 4) did not cause a significant reduction in baseline Lp compared to normal control 
group (n = 6), but lowered the mean value from 1.5 ± 0.1 to 1.1 ± 0.2 (× 10-7 cm/s/cm H2O). 
When each vessel was exposed to platelet activating factor (PAF, 10 nM) that is known to 
cause transient increases in Lp(Zhou and He, 2011), microvessels in DEX-treated rats 
showed significantly attenuated Lp response. The mean peak Lp value was reduced from 
11.1 ± 1.8 (normal control) to 6.0 ± 0.4(× 10-7 cm/s/cm H2O, Figure 1C). We then assessed 
flux of Ad from the apical to basolateral side of HUVEC monolayer and found a reduced 
total amount of Ad in basolateral media after DEX treatment (Fig. 1D-F). When monitoring 
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absolute flux rates in control cells, Ad flux rate was 4.4 ± 0.12 cm s-1 x 10-9 which 
significantly decreased after DEX treatment to 3.2 ± 0.30cm s-1 x 10-9 (Fig. 1D). Following 
a 24 h flux period, Ad levels detected in basolateral media were 64.8 ± 5.7 ng/mL. Using 
Western blotting to examine various oligomeric forms of Ad LMW (~90 kDa), MMW 
(~180 kDa) and HMW (>250 kDa), we found that flux of all forms was reduced by DEX 
(Fig. 1E&F). Additionally, the functional activity of Ad appearing in basolateral media was 
confirmed by using this media to treat L6 skeletal muscle cells and H9C2 cells derived 
from rat heart ventricle. In both cell types the media increased AMPK phosphorylation 
(supplementary Figure 1A-B) 
2.4.2 Dexamethasone treatment alters transcript and protein abundance of select TJ 
proteins in HUVEC monolayers 
A tissue expression profile of transcripts encoding 26 TJ proteins in HUVECs revealed the 
presence of 15 (Fig. 2A). The most abundant transcript was found to be CLDN-11, while 
CLDN-7, CLDN-12 and ZO-1 exhibited relatively high abundance and OCLN, TRIC, 
CLDN-10 and CLDN-15 exhibited moderate levels of abundance (Fig 2A). Transcripts not 
detected in HUVECs included CLDN-3, -4, -5, -8, -9, -16, -17, -18, -19, -23 and -25 (Fig. 
2A & Supplementary figure 1C). Human kidney cDNA was used as a positive control for 
transcripts that were not detected in HUVECs (Supplementary figure 1C). To explore the 
response of TJ proteins to DEX- treatment, we first compared mRNA abundance of 
expressed target genes in HUVECs. DEX increased CLDN-6 mRNA abundance while 
CLDN-2, -20, -22, -24 and ZO-1 mRNA showed significant decreases (Fig. 2B). DEX 
treatment had no significant effect on mRNA encoding OCLN, TRIC, CLDN-1, -7, -10, -
11 -12 and -15(Fig. 2B). Following DEX treatment, the protein abundance of CLDN-1, -
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7, -11 and ZO-1 was examined and found to be significantly upregulated following DEX 
treatment when compared to the control group (Fig. 2C, D). On the other hand, CLDN-10 
protein levels were significantly decreased when compared with the expression in control 
conditions (Fig. 2C, D). In order to validate the functional significance of Dex-induced 
changes in expression of tight juntion proteins we used shRNA to target claudin-7 and this 
effectively reduced its expression by 71% on average (Fig. 3A). Furthermore, HUVEC 
with reduced levels of claudin-7 showed reduced TEER and a small but significant increase 
in flux of adiponectin from apical to basolateral side (Figs 3B-D). 
2.4.3 Examination of changes in transcellular endothelial flux 
 The possible contribution of transcellular receptor-mediated Ad movement across 
HUVEC monolayers was then investigated by analysis of expression levels of three 
identified Ad receptors. Intracellular Ad content in these cells was detected, although at 
low level, and expression levels did not change significantly with DEX treatment (Fig. 4A). 
However, DEX significantly increased T-cadherin protein abundance (Fig. 4B), but had no 
effect on protein abundance of AdipoR1 and AdipoR2 (Fig. 4C).  
2.4.4 Skeletal muscle Ad content in a rat model of exogenous glucocorticoid-induced 
diabetes 
 We then examined whether the increased endothelial cell barrier tightness observed 
after DEX treatment would be paralleled in a diabetic rodent model of chronic 
glucocorticoid exposure. As expected based on previously published work (D'Souza A et 
al., 2012; Shikatani et al., 2012; Shpilberg et al., 2012), two weeks of exogenous 
corticosterone (CORT) treatment resulted in severe fasting hyperinsulinemia and impaired 
glucose tolerance (Supp Fig 2A). In addition, CORT treatment caused mild/moderate 
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elevations in fasted blood glucose concentrations (5.12± 0.2 mM to 8.3 ± 1.88 mM, Supp 
Fig 2B) despite the significantly increased fasted insulin concentrations (0.76±0.25 ng/ml 
to 4.68±0.72 ng/ml , Supp Fig 2C). CORT treatment also caused a change in skeletal 
muscle fibre type composition; a switch from predominantly slow to fast-twitch skeletal 
muscle fibers, within the tibialis anterior muscle (Supp Fig 2D).  
 To explore whether CORT-treatment affects circulating Ad levels, we measured 
plasma Ad levels in these animals before CORT pellet implantation and at 7 days post 
pellet implantation, at 0800h. Circulating Ad levels were unaffected by CORT treatment 
(Fig 5. A). Interestingly, there was an apparent elevation in skeletal muscle Ad mRNA 
levels (Fig 5. B), yet Ad protein content was significantly reduced (Fig 5. C&D). Upon 
immunohistochemical analyses, we also observed that the total amount of Ad was 
decreased in skeletal muscle from the COR-treated rats versus control rats (Fig 5. E-H). 
Dystrophin, was used to assess the structural integrity of the skeletal muscle and was 
unaffected by CORT treatment. Representative images are shown (Fig 5. E) with 
quantification of the total and intracellular Ad signal (Fig 5. G-H). Since CORT-treatment 
is known to preferentially target fast-twitch skeletal muscle (Beaudry et al., 2015), 
representative images accordingly depict smaller IIb/x fiber area (Supp Fig. 2D) within the 
CORT-treated rats. CORT-treatment was also found to cause a significant reduction in 
individual myocyte size (Fig. 5F).  
2.4.5 AdipoR abundance in a rat model of exogenous glucocorticoid-induced diabetes 
 Both Ad receptor isoforms (AdipoR1 and AdipoR2) genes were expressed in rat 
soleus skeletal muscle and although an apparent increase in AdipoR1 mRNA abundance 
was seen in the diabetic rat model, neither was significantly altered (Fig. 6 A,B). However, 
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a significantly increased level of ADIPO-R1 protein (approximately 3.4 fold compared to 
the control) was seen (Fig. 6F). There were no changes in ADIPO- R2 nor in T- Cadherin 
protein levels (Fig. 6E, G). 
2.4.6 CORT treatment altered Tight Junction genes in rat soleus skeletal muscle after 
2 weeks 
 We then measured changes in mRNA abundance of tight junction, Cldn-1, -2, -3, -
4,-5, -6, -7, -9, -10, -11,  -12, -24,-14, -15, -19, -20, -22, -23 and Ocln, Tricand Z0-1 were 
found to be no significant changes  with in diabetic rat skeletal muscle (Fig. 6C), with  only 
Cldn -5, -10, -11, -22 significantly decreased (Fig. 6D). 
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Figure 1: Effects of DEX on permeability. HUVECs (Human Umbilical Vein Endothelial 
Cell) were seeded onto permeable polyethylene terephthalate (PET) filters and treated with 
or without 1µM of DEX every other day in both top and bottom of compartments. Tightness 
of the monolayer was measured on the 5th day of DEX treatment.  A)  Transendothelial 
Electrical Resistance (TEER). B) [3H]PEG-4000 permeability across HUVEC monolayer. 
C) Measurements of hydraulic conductivity (Lp) in individually perfused mesenteric 
venulesfrom normal (n = 6) and Dex-treated(n = 4) rats. DEX treatment significantly 
attenuated the Lp responses to PAF that was known to cause transient increases inLp.  D-
F) 10 µg of full-length Ad was added onto the apical side. After 24 hrs, the medium on 
basolateral was collected. D) Total Ad amount was quantified using ELISA. E) The 
collected basolateral medium was concentrated and separated by PAGE. 3 forms of Ad are 
labeled as LMW (~90 kDa), MMW (~180 kDa), HMW (>250 kDa). F) Representative 
Western blot for full-length Ad flux across control and Dex-treated monolayers. Data are 
expressed as mean values ± SEM (n = 4-8). *Significant difference (P ≤ 0.05) from control 
(Con) group. 
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Figure 2: Effect of DEX on Tight Junction Components. A) mRNA abundance by qRT-PCR 
analysis. HUVECs grown to confluence on permeable PET inserts. Total RNA was isolated 
from control cells on the 5th day. Transcript abundance was normalized to GAPDH and 
each gene examined was expressed relative to OCLN transcript abundance.  B) TJ 
transcript levels in DEX-treated cells were normalized to GAPDH, and expressed relative 
to the control group (Blue - increasing compared to control; Green- decreasing compared 
to control). Data are expressed as mean values ± SEM (n = 3-5). C) Protein abundance in 
HUVECs grown on cell culture inserts. Protein abundance were normalized toβ-ACTIN, 
and expressed relative to the control group. D) Representative Western blots of CLDN- 1, 
-7, -10, -11, -15, TRI, OCC, Z0-1. Data are expressed as mean values ± SEM (n = 3-8). * 
indicates significant difference (P ≤ 0.05) from control (Con) group.  
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Figure 3: Knockdown of claudin-7 alters transendothelial electrical resistance and 
adiponectin flux. We used shRNA to reduce levels of claudin-7 in HUVEC and average 
efficiency of knockdown was 71% with a representative Western blot shown in A. In cells 
transfected with scrambled (Control) or claudin-7 shRNA we then tested TEER (B) and 
flux of adiponectin with representative Western blot shown in C and quantitation in D. In 
B and D values are mean ± SEM (n = 3) and *indicates significant difference (P ≤ 0.05) 
	 39	
from control group.
 
Figure 4: Expression of Ad and its receptors in HUVEC. A) Ad expression in HUVECs 
treated with DEX after 5 days. B) T- CADHERIN expression in HUVECs with DEX 
treatment.  C) ADIPO -R1/ -R2 expression in HUVECs. Data are expressed as mean values 
± SEM (n = 3-6). *indicates significant difference (P ≤ 0.05) from control (Con) group. 
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Figure 5: Ad level in CORT treated animals. A) Using ELISA, circulating Ad was 
calculated in 1 week treated rat serum. B) Ad mRNA expression after 14 days of CORT. 
C&D) Representative Western blotting and quantitation of reduced Ad (~30 kDa) in soleus 
skeletal muscle. E) Immunohistochemical detection of dystrophin (green), Ad (red) in 
skeletal muscle isolated from rats after 2 weeks of CORT treatment, together with 
quantitation in F. G) Quantification of changes in intracellular Ad levels and H) cell 
number. Quantification of Ad shown as the intensity expressed per cell in arbitrary units 
and are expressed as mean values ± SEM (n = 3-5).* indicates significant difference (P ≤ 
0.05) from control (Con) group.  
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Figure 6: Ad receptor expression in skeletal muscle. Rats were treated with CORT for 2 
weeks. A,B) mRNA expression of Ad and its receptors after 14 days of CORT. Data are 
expressed as mean values ± SEM (n = 4-5). C-D) mRNA profile of tight junction in soleus 
skeletal muscle isolated from 2 weeks CORT- treated rats.  mRNA abundance by qRT-PCR 
analysis. Transcript abundance was normalized to GAPDH mRNA abundance, and mRNA 
abundance for each gene examined was expressed relative to control group transcript 
abundance. Control group gene transcript were normalized to 1. C) mRNA profile of TJ 
that are increased after 2 weeks CORT treatment compared to control. Blue- CORT- 
treated, Red- Control. D) TJ genes that are decreased after 2 weeks of CORT treatment.  . 
E- G) Protein expression in soleus. E) T- CADHERIN. F) Ad receptor 1. G) Ad receptor 2. 
Data are expressed as mean values ± SEM (n = 3). * indicates significant difference (P ≤ 
0.05) from control group 
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2.5 Discussion 
Glucocorticoids are potential mediators of endothelium permeability. Our study 
was designed investigate the its influence on endothelium permeability and consequently 
the changes in Ad movement across the endothelium barrier and the underlying 
mechanism. More recently, a similar proposed mechanism for regulation of Ad action was 
suggested both by us and others (Rutkowski et al., 2014; Yoon et al., 2014). To the best of 
our knowledge, the regulation of this process by glucocorticoids had not been studied 
before. Our vitro model using DEX treated HUVEC and CORT treated rats to integrate the 
established observations that glucocorticoids can restrict paracellular transport across 
various endothelia (Keaney and Campbell, 2015; Rao et al., 2015; Rochfort and Cummins, 
2015) with the fact that glucocorticoids, commonly prescribed medications, have numerous 
side effects, including insulin resistance and diabetes (Beaudry et al., 2015). Furthermore, 
we examined whether the emerging phenomenon that transendothelial movement of Ad 
may regulate the anti-diabetic effects of this hormone and whether this was regulated by 
glucocorticoids (Rutkowski et al., 2014; Yoon et al., 2014). Specifically, our approach 
involved the use of endothelial cell monolayers and individually perfused intact 
microvessels to examine whether glucocorticoid altered Ad flux was through reduced 
microvessel permeability. We also used a rat model of diabetes induced by exogenous 
glucocorticoid treatment to determine changes in Ad content in muscle as well as peripheral 
insulin sensitivity. 
 
As indicated in the introduction, strong rationale for this work comes from previous 
studies with other circulating hormones, most notably insulin. Concentrations of insulin at 
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the cell surface have been shown to be very different from those observed in plasma in 
microdialysis experiments (Herkner et al., 2003; Sjostrand et al., 1999), direct interstitial 
sampling (Bodenlenz et al., 2005) and lymph measurements (Chiu et al., 2008; Yang et al., 
1994). It was noted that insulin-mediated glucose uptake lagged behind the increase in 
plasma insulin (Freidenberg et al., 1994), whereas in cultured skeletal muscle cells, insulin-
mediated glucose uptake occurs within 10 min (Somwar et al., 2001). The time delay seen 
in vivo (Freidenberg et al., 1994) reflects a delay in insulin access to the myocyte which is 
mediated in part via altered paracellular or transcellular endothelial transport. Thus, 
modification of access to skeletal muscle can have major effects on insulin action and 
metabolism, suggesting that reaching the interstitial space is the limiting factor for insulin-
mediated glucose uptake (Kolka and Bergman, 2012). Indeed, delivery of insulin to the 
interstitial space has been shown to be altered by diet (Kubota et al., 2011).  
 
We confirmed the ability of the synthetic glucocorticoid DEX to alter endothelial 
transport properties, in this case of HUVEC monolayers, as indicated by changes in TEER 
and PEG-4000. Similar effects were observed in DEX-treated rats, where we saw a 
significant reduction of permeability in rat mesenteric venules. We then showed that DEX 
reduced Ad flux across cultured endothelial monolayers by ELISA detection of total Ad 
content. Western blotting of Ad isoforms indicated that all three oligomeric forms of Ad 
(trimer, hexamer and oligomer) were reduced in basolateral media from DEX-treated cells, 
and although the magnitude of change was more evident in the case of LMW adiponectin, 
all isoforms were significantly altered and we do not believe this data infers a preferential 
restriction of LMW flux. This demonstration of restricted flux is important to establish 
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from several perspectives. First, many studies have suggested that oligomeric high 
molecular weight complexes of Ad are most tightly correlated with insulin resistance (Liu 
et al., 2007; Pajvani et al., 2004). Second, the concept that endothelial transport regulated 
Ad action was also proposed by a recent study which estimated the size of different Ad 
forms by calculating a Stokes radius (Rutkowski et al., 2014). The Stokes radii were 3.96 
nm for trimeric Ad, 6.01 nm for hexameric Ad and 10.1 nm for various HMW oligomeric 
forms (Rutkowski et al., 2014) and these sizes are likely to be in the range that can be 
physically obstructed or facilitated by changes in endothelial cell tight junction size. 
Indeed, it was concluded that Ad bioavailability and action in target cells was attenuated 
under stressed conditions due to reduced trans-endothelial transport (Rutkowski et al., 
2014). We concur that regulation of Ad flux across endothelium is particularly relevant 
since the target tissues where Ad mediates its physiological effects have a wide-range of 
endothelial permeability. Liver, for example has highly fenestrated endothelium that may 
permit the passage of HMW Ad, which has potent effects on hepatic metabolism. In 
contrast, the central effects of HMW Ad may be limited by its transport across the 
comparatively tighter blood brain barrier (Yoon et al., 2014).  
 
The well-established effect of glucocorticoids to restrict endothelial transport has 
been proposed to be mediated via regulation of TJ and adherens junction (AJ) proteins 
(Blecharz et al., 2008; Felinski and Antonetti, 2005). Strands of transmembrane and 
cytosolic proteins form TJ and AJ complexes that regulate permeability between 
endothelial cells (Gunzel and Fromm, 2012). Functional characteristics of the vertebrate 
TJ complex are dependent on the variable assemblage of TJ proteins such as occludin 
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(OCLN), tricellulin (TRIC) and in particular, claudins (CLDNs) which directly establish 
the TJ barrier and form the backbone of TJ strands, while cytosolic ZO-1 and other cortical 
TJ proteins provide structural support to the TJ complex (Gunzel and Fromm, 2012). The 
CLDN superfamily consists of at least 27 isoforms in mammals and the incorporation of 
specific CLDN isoforms in TJs can modulate TJ barrier function by making the paracellular 
pathway tighter or leakier (Gunzel and Yu, 2013). The main observations in our study were 
increased CLDN-7 and decreased CLDN-10 protein abundance in HUVEC in response to 
DEX and these changes may underlie the functional properties of paracellular transport 
limiting Ad flux. Little is known about CLDN-7, although CLDN-7 knockout is lethal in 
murine models and it seems that CLDN-7 most likely facilitates anion movement across 
vertebrate epithelia. CLDN-7 was previously found to form a complex with the epithelial 
cell adhesion molecule (EpCAM) which enhanced cell-cell interaction (Krug et al., 2012; 
Verma and Molitoris, 2015) . We suggested that the functional role of CLDN-7 in our 
model is tightening of the endothelium in association with an increase in abundance, and 
that this may help to explain, in part, the restricted movement of Ad in DEX-treated 
HUVEC as well CORT-treated rats. Further supporting this idea, a reprevious studies 
which have found that CLDN-7 (-/-) can cause colonic inflammation and enhance the 
paracellular flux of small organic solutes (Tanaka et al., 2015), as well as observations that 
CLDN-7 (-/-) results in the presence of intercellular gaps below TJs and cell matrix 
loosening (Ding et al., 2012). Thus, we used shRNA to target claudin-7 in HUVEC and 
observed that this caused a decrease in TEER and increase in adiponectin flux across 
monolayers, further indicating an important mechanistic role for Dex-mediated changes in 
claudin-7 expression. Interestingly, another group found that NLRP3 inflammasome 
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promoted endothelial disruption via production of HMGB1 to disrupt the junctions and 
increased paracellular permeability (Chen et al., 2015). Finally, (Tatum et al., 2010) 
reported that urine Na(+), Cl(-), and K(+) were significantly increased in CLDN-7(-/-) mice 
compared with that of CLDN-7(+/+) mice. Taken together, the studies outlined above and 
our data indicate an important functional consequence for CLDN-7 reduction and 
compromised epithelial permeability as the result of tight junction disruption, and this 
supports the view that increased CDLN-7 abundance, as seen in these experiments, may 
contribute to endothelial tightening and reduced Ad flux. 
 
In contrast, CLDN-10 isoforms in vertebrate epithelia have been described to impart both 
charge and size selective properties to the paracellular pathway. Previous studies 
investigated the role of CLDN-10 deficient mice using Cre-Lox found that serum 
phosphate concentration was 28% higher and serum Mg2+ concentration was almost two-
fold higher in cKO mice compared with controls. However, the same study also found that 
CLDN-10 transports molecules in a charged selective manner (Breiderhoff et al., 2012). 
To the best of our knowledge, Ad is uncharged. Therefore, the transport of Ad is less likely 
to be affected by CLDN-10. Nevertheless, it would be very interesting to explore whether 
the consistent decrease in CLDN-10 observed in this study has a functional role in the 
modulation of Ad transport across the endothelium barrier. 
In the glucocorticoid-induced diabetic rodent model used here, a decrease in 
CLDN-10 mRNA expression in skeletal muscle was also observed. Although changes in 
expression profiles of other tight junction proteins do not entirely match the changes in 
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HUVEC treated directly with DEX, this is not entirely surprising since there are multiple 
factors impinging upon tight junction protein expression in skeletal muscle tissue in vivo.  
We believe that reduced paracellular transport is the main mechanism of reduced 
Ad flux observed, yet we also tested possible indicators of altered transendothelial flux 
(Yoon et al., 2014). In DEX-treated endothelial cells, there was no major change in 
ADIPO-R1 or ADIPO-R2 mRNA and protein expression, although in skeletal muscle 
homogenates, ADIPO-R1 protein expression levels increased significantly in CORT-
treated animals. This may reflect a compensatory mechanism to reduced Ad availability in 
order to increase sensitivity to available Ad. We also observed that DEX increased 
expression of T-cadherin in HUVEC. T-cadherin has been identified as a non-functional 
receptor for Ad (Hug et al., 2004). This is in agreement with a previous study showing that 
DEX enhanced T-cadherin expression in human osteosarcoma cells (Bromhead et al., 
2006). One possible interpretation of our finding is that binding to endothelial T-cadherin 
may trap Ad in the vasculature, as has recently been proposed (Matsuda et al., 2015). 
We also investigated potential alterations in endothelial transport of Ad in a rodent 
model of glucocorticoid-induced diabetes (Shpilberg et al., 2012). In these rats, we found 
normal circulating Ad levels but significantly reduced total Ad protein content within 
skeletal muscle without an accompanying decrease in muscle Ad gene expression. This 
suggests less flux of Ad from circulation could be a contributory mechanism. Indeed, upon 
immunohistochemical analysis we found reduced Ad content in the interstitial space. 
Although not a direct comparison to the in vitro studies we used here, it suggests that 
skeletal muscle Ad availability, and thus action, may be limited in this animal model 
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possibly contributing to its diabetic phenotype (Beaudry et al., 2013; Beaudry et al., 2015; 
Beaudry et al., 2014; Shpilberg et al., 2012; Yoon et al., 2014). 
In conclusion, our study indicates that glucocorticoid-mediated tightening can 
reduce flux of Ad across endothelial monolayers, and that this may be due to alterations in 
the expression profile of tight junction proteins. Furthermore, in a rat model of diabetes 
induced by exogenous glucocorticoids, we observed reduced interstitial and intracellular 
levels of Ad in skeletal muscle. Thus, we propose that reduced Ad action in target tissues, 
as a consequence of reduced endothelial flux from circulation to interstitial space, may 
contribute to the diabetic phenotype occurring after glucocorticoid treatment. Since 
glucocorticoids are one of the most commonly prescribed medications, our discovery of 
reduced Ad transport in response to glucocorticoids is a particularly important and novel 
finding with potentially far-reaching consequences.  
  
	 49	
 
Supp. Figure 1: A) Effect of treatment with HUVEC-conditioned basolateral medium from 
Ad flux experiments onp-AMPK and p-p38 MAPK phosphorylation in rat L6 and H9C2. 
Phosphorylated AMPK and p_p38 MAPK protein abundance was normalized to β-actin, 
and expressed relative to the corresponding time-matched control group. In (C), Western 
blots of p-AMPK, phospho-p38 MAPKare shown. Data are expressed as mean values ± 
SEM (n = 3). B) Non-detected genes in figure 1(C) was ran on 1% gel in order to confirm 
the absence. Human kidney was used as positive control.  Data are expressed as mean 
values ± SEM (n = 3 - 16). *Significant difference (P ≤ 0.05) from control (Con) group. 
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Supp. Figure 2: Circulation of metabolites in CORT treated rats. A) Glucose tolerance in 
response to an oral glucose tolerance test (OGTT). B) Fasted blood glucose and C) fasted 
insulin concentrations measured at the onset of the OGTT after 12 days of CORT treatment. 
D) Representative images of the tibialis anterior (TA) depicting fiber type staining with 
Metachromatic myosin ATPase. Data are expressed as mean values ± SEM (n =5 ). 
*Significant difference (P ≤ 0.05) from control (Con) group. 
  
	 51	
Copyright Permission  
 
 
  
	 52	
2.6 References  
Agarwal A, Sarwar S, Sepah YJ & Nguyen QD 2015 What have we learnt about the 
management of diabetic macular edema in the antivascular endothelial growth factor and 
corticosteroid era? Curr Opin Ophthalmol 26 177-183. 
Arita Y, Kihara S, Ouchi N, Maeda K, Kuriyama H, Okamoto Y, Kumada M, Hotta K, 
Nishida M, Takahashi M, et al. 2002 Adipocyte-derived plasma protein adiponectin acts 
as a platelet-derived growth factor-BB-binding protein and regulates growth factor-
induced common postreceptor signal in vascular smooth muscle cell. Circulation 105 
2893-2898. 
Barrett EJ, Wang H, Upchurch CT & Liu Z 2011 Insulin regulates its own delivery to 
skeletal muscle by feed-forward actions on the vasculature. Am J Physiol Endocrinol 
Metab 301 E252-263. 
Beaudry JL, D'Souza A M, Teich T, Tsushima R & Riddell MC 2013 Exogenous 
glucocorticoids and a high-fat diet cause severe hyperglycemia and hyperinsulinemia and 
limit islet glucose responsiveness in young male Sprague-Dawley rats. Endocrinology 154 
3197-3208. 
Beaudry JL, Dunford EC, Leclair E, Mandel ER, Peckett AJ, Haas TL & Riddell MC 2015 
Voluntary exercise improves metabolic profile in high-fat fed glucocorticoid-treated rats. 
J Appl Physiol (1985) 118 1331-1343. 
Beaudry JL, Dunford EC, Teich T, Zaharieva D, Hunt H, Belanoff JK & Riddell MC 2014 
Effects of selective and non-selective glucocorticoid receptor II antagonists on rapid-onset 
diabetes in young rats. PLoS One 9 e91248. 
Blecharz KG, Drenckhahn D & Forster CY 2008 Glucocorticoids increase VE-cadherin 
expression and cause cytoskeletal rearrangements in murine brain endothelial cEND cells. 
J Cereb Blood Flow Metab 28 1139-1149. 
Bodenlenz M, Schaupp LA, Druml T, Sommer R, Wutte A, Schaller HC, Sinner F, Wach 
P & Pieber TR 2005 Measurement of interstitial insulin in human adipose and muscle tissue 
under moderate hyperinsulinemia by means of direct interstitial access. Am J Physiol 
Endocrinol Metab 289 E296-300. 
Breiderhoff T, Himmerkus N, Stuiver M, Mutig K, Will C, Meij IC, Bachmann S, Bleich 
M, Willnow TE & Muller D 2012 Deletion of claudin-10 (Cldn10) in the thick ascending 
limb impairs paracellular sodium permeability and leads to hypermagnesemia and 
nephrocalcinosis. Proc Natl Acad Sci U S A 109 14241-14246. 
	 53	
Bromhead C, Miller JH & McDonald FJ 2006 Regulation of T-cadherin by hormones, 
glucocorticoid and EGF. Gene 374 58-67. 
Chen Y, Pitzer AL, Li X, Li PL, Wang L & Zhang Y 2015 Instigation of endothelial Nlrp3 
inflammasome by adipokine visfatin promotes inter-endothelial junction disruption: role 
of HMGB1. J Cell Mol Med 19 2715-2727. 
Chiu JD, Richey JM, Harrison LN, Zuniga E, Kolka CM, Kirkman E, Ellmerer M & 
Bergman RN 2008 Direct administration of insulin into skeletal muscle reveals that the 
transport of insulin across the capillary endothelium limits the time course of insulin to 
activate glucose disposal. Diabetes 57 828-835. 
Clark AR & Belvisi MG 2012 Maps and legends: the quest for dissociated ligands of the 
glucocorticoid receptor. Pharmacol Ther 134 54-67. 
D'Souza A M, Beaudry JL, Szigiato AA, Trumble SJ, Snook LA, Bonen A, Giacca A & 
Riddell MC 2012 Consumption of a high-fat diet rapidly exacerbates the development of 
fatty liver disease that occurs with chronically elevated glucocorticoids. Am J Physiol 
Gastrointest Liver Physiol 302 G850-863. 
Dadson K, Liu Y & Sweeney G 2011 Adiponectin action: a combination of endocrine and 
autocrine/paracrine effects. Front Endocrinol (Lausanne) 2 62. 
Ding L, Lu Z, Foreman O, Tatum R, Lu Q, Renegar R, Cao J & Chen YH 2012 
Inflammation and disruption of the mucosal architecture in claudin-7-deficient mice. 
Gastroenterology 142 305-315. 
Felinski EA & Antonetti DA 2005 Glucocorticoid regulation of endothelial cell tight 
junction gene expression: novel treatments for diabetic retinopathy. Curr Eye Res 30 949-
957. 
Freidenberg GR, Suter S, Henry RR, Nolan J, Reichart D & Olefsky JM 1994 Delayed 
onset of insulin activation of the insulin receptor kinase in vivo in human skeletal muscle. 
Diabetes 43 118-126. 
Gunzel D & Fromm M 2012 Claudins and other tight junction proteins. Compr Physiol 2 
1819-1852. 
Gunzel D & Yu AS 2013 Claudins and the modulation of tight junction permeability. 
Physiol Rev 93 525-569. 
Herkner H, Klein N, Joukhadar C, Lackner E, Langenberger H, Frossard M, Bieglmayer 
C, Wagner O, Roden M & Muller M 2003 Transcapillary insulin transfer in human skeletal 
muscle. Eur J Clin Invest 33 141-146. 
	 54	
Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS & Lodish HF 2004 T-cadherin is a receptor 
for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad 
Sci U S A 101 10308-10313. 
Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K & Tobe K 2006 Adiponectin and 
adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin 
Invest 116 1784-1792. 
Keaney J & Campbell M 2015 The dynamic blood-brain barrier. FEBS J 282 4067-4079. 
Kolka CM & Bergman RN 2012 The barrier within: endothelial transport of hormones. 
Physiology (Bethesda) 27 237-247. 
Krause MP, Liu Y, Vu V, Chan L, Xu A, Riddell MC, Sweeney G & Hawke TJ 2008 
Adiponectin is expressed by skeletal muscle fibers and influences muscle phenotype and 
function. Am J Physiol Cell Physiol 295 C203-212. 
Krug SM, Gunzel D, Conrad MP, Lee IF, Amasheh S, Fromm M & Yu AS 2012 Charge-
selective claudin channels. Ann N Y Acad Sci 1257 20-28. 
Kubota N, Yano W, Kubota T, Yamauchi T, Itoh S, Kumagai H, Kozono H, Takamoto I, 
Okamoto S, Shiuchi T, et al. 2007 Adiponectin stimulates AMP-activated protein kinase 
in the hypothalamus and increases food intake. Cell Metab 6 55-68. 
Kubota T, Kubota N, Kumagai H, Yamaguchi S, Kozono H, Takahashi T, Inoue M, Itoh 
S, Takamoto I, Sasako T, et al. 2011 Impaired insulin signaling in endothelial cells reduces 
insulin-induced glucose uptake by skeletal muscle. Cell Metab 13 294-307. 
Kusminski CM, McTernan PG, Schraw T, Kos K, O'Hare JP, Ahima R, Kumar S & Scherer 
PE 2007 Adiponectin complexes in human cerebrospinal fluid: distinct complex 
distribution from serum. Diabetologia 50 634-642. 
Lin KT & Wang LH 2016 New dimension of glucocorticoids in cancer treatment. Steroids 
111 84-88. 
Liu Y, Retnakaran R, Hanley A, Tungtrongchitr R, Shaw C & Sweeney G 2007 Total and 
high molecular weight but not trimeric or hexameric forms of adiponectin correlate with 
markers of the metabolic syndrome and liver injury in Thai subjects. J Clin Endocrinol 
Metab 92 4313-4318. 
Matsuda K, Fujishima Y, Maeda N, Mori T, Hirata A, Sekimoto R, Tsushima Y, Masuda 
S, Yamaoka M, Inoue K, et al. 2015 Positive feedback regulation between adiponectin and 
T-cadherin impacts adiponectin levels in tissue and plasma of male mice. Endocrinology 
156 934-946. 
	 55	
Nanayakkara G, Kariharan T, Wang L, Zhong J & Amin R 2012 The cardio-protective 
signaling and mechanisms of adiponectin. Am J Cardiovasc Dis 2 253-266. 
Neumeier M, Weigert J, Buettner R, Wanninger J, Schaffler A, Muller AM, Killian S, 
Sauerbruch S, Schlachetzki F, Steinbrecher A, et al. 2007 Detection of adiponectin in 
cerebrospinal fluid in humans. Am J Physiol Endocrinol Metab 293 E965-969. 
Ogilvie RW & Feeback DL 1990 A metachromatic dye-ATPase method for the 
simultaneous identification of skeletal muscle fiber types I, IIA, IIB and IIC. Stain Technol 
65 231-241. 
Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, Wagner JA, Wu 
M, Knopps A, Xiang AH, et al. 2004 Complex distribution, not absolute amount of 
adiponectin, correlates with thiazolidinedione-mediated improvement in insulin 
sensitivity. J Biol Chem 279 12152-12162. 
Peters KE, Beilby J, Cadby G, Warrington NM, Bruce DG, Davis WA, Davis TM, 
Wiltshire S, Knuiman M, McQuillan BM, et al. 2013 A comprehensive investigation of 
variants in genes encoding adiponectin (ADIPOQ) and its receptors (ADIPOR1/R2), and 
their association with serum adiponectin, type 2 diabetes, insulin resistance and the 
metabolic syndrome. BMC Med Genet 14 15. 
Rao A, Pandya V & Whaley-Connell A 2015 Obesity and insulin resistance in resistant 
hypertension: implications for the kidney. Adv Chronic Kidney Dis 22 211-217. 
Rochfort KD & Cummins PM 2015 The blood-brain barrier endothelium: a target for pro-
inflammatory cytokines. Biochem Soc Trans 43 702-706. 
Rutkowski JM, Halberg N, Wang QA, Holland WL, Xia JY & Scherer PE 2014 
Differential transendothelial transport of adiponectin complexes. Cardiovasc Diabetol 13 
47. 
Shikatani EA, Trifonova A, Mandel ER, Liu ST, Roudier E, Krylova A, Szigiato A, 
Beaudry J, Riddell MC & Haas TL 2012 Inhibition of proliferation, migration and 
proteolysis contribute to corticosterone-mediated inhibition of angiogenesis. PLoS One 7 
e46625. 
Shpilberg Y, Beaudry JL, D'Souza A, Campbell JE, Peckett A & Riddell MC 2012 A rodent 
model of rapid-onset diabetes induced by glucocorticoids and high-fat feeding. Dis Model 
Mech 5 671-680. 
Sjostrand M, Holmang A & Lonnroth P 1999 Measurement of interstitial insulin in human 
muscle. Am J Physiol 276 E151-154. 
	 56	
Somwar R, Kim DY, Sweeney G, Huang C, Niu W, Lador C, Ramlal T & Klip A 2001 
GLUT4 translocation precedes the stimulation of glucose uptake by insulin in muscle cells: 
potential activation of GLUT4 via p38 mitogen-activated protein kinase. Biochem J 359 
639-649. 
Tanaka H, Takechi M, Kiyonari H, Shioi G, Tamura A & Tsukita S 2015 Intestinal deletion 
of Claudin-7 enhances paracellular organic solute flux and initiates colonic inflammation 
in mice. Gut 64 1529-1538. 
Tatum R, Zhang Y, Salleng K, Lu Z, Lin JJ, Lu Q, Jeansonne BG, Ding L & Chen YH 
2010 Renal salt wasting and chronic dehydration in claudin-7-deficient mice. Am J Physiol 
Renal Physiol 298 F24-34. 
Verma SK & Molitoris BA 2015 Renal endothelial injury and microvascular dysfunction 
in acute kidney injury. Semin Nephrol 35 96-107. 
Wang Y, Xu A, Knight C, Xu LY & Cooper GJ 2002 Hydroxylation and glycosylation of 
the four conserved lysine residues in the collagenous domain of adiponectin. Potential role 
in the modulation of its insulin-sensitizing activity. J Biol Chem 277 19521-19529. 
Witt KA & Sandoval KE 2014 Steroids and the blood-brain barrier: therapeutic 
implications. Adv Pharmacol 71 361-390. 
Won SM, Lee JH, Park UJ, Gwag J, Gwag BJ & Lee YB 2011 Iron mediates endothelial 
cell damage and blood-brain barrier opening in the hippocampus after transient forebrain 
ischemia in rats. Exp Mol Med 43 121-128. 
Wood CM, Gilmour KM, Perry SF, Part P & Walsh PJ 1998 Pulsatile urea excretion in 
gulf toadfish (Opsanus beta): evidence for activation of a specific facilitated diffusion 
transport system. J Exp Biol 201 805-817. 
Xu A, Yin S, Wong L, Chan KW & Lam KS 2004 Adiponectin ameliorates dyslipidemia 
induced by the human immunodeficiency virus protease inhibitor ritonavir in mice. 
Endocrinology 145 487-494. 
Yang YJ, Hope ID, Ader M & Bergman RN 1994 Importance of transcapillary insulin 
transport to dynamics of insulin action after intravenous glucose. Am J Physiol 266 E17-
25. 
Yoon N, Dang TQ, Chasiotis H, Kelly SP & Sweeney G 2014 Altered transendothelial 
transport of hormones as a contributor to diabetes. Diabetes Metab J 38 92-99. 
Yuan D & He P 2012 Vascular remodeling alters adhesion protein and cytoskeleton 
reactions to inflammatory stimuli resulting in enhanced permeability increases in rat 
venules. J Appl Physiol (1985) 113 1110-1120. 
	 57	
Yuan D, Xu S & He P 2014 Enhanced permeability responses to inflammation in 
streptozotocin-induced diabetic rat venules: Rho-mediated alterations of actin cytoskeleton 
and VE-cadherin. Am J Physiol Heart Circ Physiol 307 H44-53. 
Zhang X, Wang N, Schachat AP, Bao S & Gillies MC 2014 Glucocorticoids: structure, 
signaling and molecular mechanisms in the treatment of diabetic retinopathy and diabetic 
macular edema. Curr Mol Med 14 376-384. 
Zhou X & He P 2011 Temporal and spatial correlation of platelet-activating factor-induced 
increases in endothelial [Ca(2)(+)]i, nitric oxide, and gap formation in intact venules. Am 
J Physiol Heart Circ Physiol 301 H1788-1797. 
  
	 58	
Statement of Contribution 
Chapter 3: T. Dang contributed to planning and conducting experiments, except for the 
Prussian blue staining which was done by Dr. Subrata. Micro- CT quantification was done 
by  P. Tadi. Advice and instruction on using CLAMS was given by D. Kishi. This chapter 
was written by T. Dang and edited by Dr. G. Sweeney  
Chapter 3: Study 2 
Modification of endothelium tightness by iron & the effects of iron on glucose metabolism  
3.1 Abstract 
There is a strong, clinically-proven, link between iron overload and diabetes. 
Limiting tissue access to adiponectin by an alteration in paracellular permeability can affect 
glucose metabolism. Iron is a potential mediator of endothelium tightness. We 
hypothesized that iron restricts adiponectin access to target tissues via tightening of the 
endothelium, and hence will impair glucose clearance. First, we confirmed iron overload 
in HDMEC cells using fluorescent imaging of intracellular iron using PGSK dye, and 
further with an iron response element (IRE)-CFP reporter construct. We found that iron 
did not affect the endothelium tightness, despite inducing an elevation in ROS. To further 
elucidate iron’s effect on whole-body metabolism, we established an iron overload mouse 
model that mimics a physiological condition of hemochromatosis. We i.p. injected mice 5 
days per week for one month to test the effect of iron overload on glucose metabolism. We 
found iron deposits in various skeletal muscles, liver, and fat using intracellular iron 
imaging and Prussian blue assays. We performed glucose and insulin tolerance testing to 
show better glucose tolerance in iron overload mice. Then we used the Comprehensive Lab 
Animal Monitoring System (CLAMS) to characterize activity, but found no significant 
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change. Furthermore, we found upregulation of pAkt in gastrocnemius muscle, but no 
change in glycogen content in skeletal muscles or liver. In addition to that, visceral 
adiposity was diminished, correlating with reduced adiponectin production. However, 
circulating insulin was not affected. Lastly, the iron overload induced higher glucose 
excretion through urine.  From our study, we found that the iron treatment did not have an 
effect on endothelium tightness and adiponectin transport in vitro. However, in our in vivo 
study, we found iron overload mice exhibit better glucose tolerance and higher Akt 
phosphorylation, indicative of increased insulin signalling. Our data suggest that the 
endothelium might not be the key target of iron in altering glucose metabolism. The 
improved glucose clearance resulted mainly from pAkt upregulation as well as constant 
glucose excretion.  
 3.2 Introduction 
Excessive amounts of iron promote insulin resistance in mice, which greatly 
increases the risk for developing diabetes and its complications (Yu et al., 2015) The 
connections between iron and metabolism are well established. Hereditary 
hemochromatosis (HH) is an autosomal recessive disorder characterized by excess iron in 
the body. The most common form of this disease is caused by a mutation in the HFE gene 
resulting in a C282Y substitution in the HFE protein. The HFE protein is responsible for 
iron metabolism by acting as an iron sensor for the body, regulating iron absorption in the 
small intestine, and recycling of iron by macrophages (Feder et al., 1996). To support the 
link between iron and diabetes, a group of researchers found that HFE KO mice exhibit 
impaired glucose-stimulated insulin secretion and increased β- cell apoptosis (Cooksey et 
al., 2004). Furthermore, in thalassemia, a disorder characterized by a deficiency in the β-
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globin subunit of hemoglobin, patients become iron-overloaded from increased iron 
absorption because the body is unable to maintain a normal level of erythrocytes in the 
blood to uptake the iron that gets into the circulation through the gut (Weatherall, 1998). 
Clinical studies on thalassemia patients have found that they have insulin deficiency and 
insulin resistance, which may lead to a prediabetic state and the development of full-blown 
diabetes (Messina et al., 2002).  
The cross-talk between iron metabolism and diabetes has also been reported by 
Tanner and Lienhard, who observed co-localization of transferrin receptors with glucose 
transporters on the membrane of adipocytes in vitro. Their study suggested that the 
regulation of iron occurs in parallel with its effects on glucose transport (Tanner and 
Lienhard, 1989). Increased iron storage is associated with the development of type 2 
diabetes (Fernandez-Real et al., 2002). Ferritin is one of the key proteins regulating iron 
homeostasis and is a widely used clinical biomarker of iron status.  Clinical studies have 
shown that higher serum ferritin levels were found in patients with metabolic syndrome 
and insulin resistance. High iron levels are associated with increased risk of type 2 diabetes, 
and thus may be a prevalent cause of diabetes (Moreno et al., 2015) 
Iron is also known for its effect on elevating oxidative stress, a major causative 
factor for diabetes and its complications. In addition to elevated ROS reducing metabolic 
clearance (Toborek et al., 1992), free radicals disrupt tight junction (TJ) function by 
altering cell-cell adherence of TJ proteins and causing reorganization of the actin filament 
network (Wichmann et al., 2015; Won et al., 2011). Previous work has suggested that iron 
overload in mice leads to elevated ROS. Interestingly, it was associated with decreased 
levels of the TJ structural proteins occludin and zonula occludens 1, and hence caused a 
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disruption in TJ structure. This resulted in increased permeability in hippocampal 
endothelial cells that were isolated from the TFI-induced iron overload rat model.  
Endothelial dysfunction contributes to the pathogenesis of atherosclerosis, a 
complication of diabetes (Handa et al., 2016; Won et al., 2011). Furthermore, previous 
research found that inflammation coexisting with increased oxidative stress occurred in 
end-stage renal disease (Raj et al., 2005). ROS enter human skeletal muscles and activates 
an inflammatory cascade via activation of nuclear factor- kB (NF-kB), as well as 
upregulating the expression of various cytokines including interleukin-6, -10 (IL-6, -10) 
and tumor necrosis factor-α (TNF-α) in response to stimuli. Increased serum concentrations 
of these cytokines are associated with impaired glucose tolerance (Muller et al., 2002). A 
monolayer of endothelial cells lines the entire circulatory system of the body. This 
endothelium acts as a barrier that regulates the exchange of hormones, proteins and small 
molecules between the vascular compartment and the interstitial space (Goddard and 
Iruela-Arispe, 2013; Pries and Kuebler, 2006). The actions of a hormone or nutrient on a 
target tissue is implicitly dependent upon the ability of these factors to gain access to the 
target. Adiponectin is an important hormone to stimulate glucose clearance. Therefore, 
changing adiponectin access to the target tissue through altering permeability could alter 
glucose metabolism.  
Based on previous literature, the goals of this study were first to examine whether 
excess iron treatment causes a change in ROS production (using CellRox red) leading to 
alterations in endothelium tightness, hence changing adiponectin movement by TEER and 
flux experiments in vitro. I have developed an iron overload model that mimics the 
pathological conditions of thalassemia and hemochromatosis to examine glucose 
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metabolism. I have used well-established methods both in intro and in vivo to confirm iron 
overload i.e., intracellular iron, IRE-CFP construct, PGSK, and Prussian blue staining. To 
study whole body glucose metabolism, I used GTT and ITT to evaluate glucose clearance 
in iron overloaded mice. I also used CLAMS to characterize this new mouse model to 
evaluate respiration and ambulatory activity. Characterizing physical activity is important 
in this study as it can have a potential effect on glucose metabolism. I then examined Akt 
phosphorylation under insulin-stimulated conditions. Glucose to glycogen conversion rate 
was tested in liver and skeletal muscles using a glycogen content assay to evaluate whether 
this process contributes to changes in circulating glucose levels with iron overload. I further 
investigated circulating insulin and adiponectin levels as possible contributors to changes 
in circulating glucose using ELISA. Since adiponectin is mainly secreted by adipocytes, 
fat content was also evaluated by isolated fat weight and whole body micro-CT scan.  
3.3 Materials and Methods  
 
3.3.1 HDMEC culture and treatments  
Human dermal microvascular endothelial cells (HDMECs) were obtained from 
ATCC (Manassas, VA, USA) and grown at 37°C and 5% CO2 on uncoated T75 flasks in 
vascular cell basal medium (ATCC, PCS-100-030) containing 10% fetal bovine serum 
(FBS), VEGF endothelial cell growth kit without hydrocortisone hemisuccinate (ATCC, 
PCS-100-041), 100 units/mL penicillin, and 100 µg/mL streptomycin. Following two 
passages, cells were trypsinized and transferred to medium containing 10% dimethyl 
sulfoxide (DMSO), frozen as aliquots in liquid nitrogen and designated as HDMECs at 
passage 3 (P3). For experiments, P3 aliquots of HDMECs were quickly thawed, plated to 
uncoated T75 flasks, and grown to ~90% confluence in medium described above. Cells 
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were then trypsinated, pelleted by centrifugation (380 x g, 10 min) and gently resuspended 
in vascular cell basal medium containing 2% FBS, VEGF endothelial cell growth kit 
without hydrocortisone hemisuccinate, 100 units/mL penicillin, and 100 µg/mL 
streptomycin. Cells were counted using a haemocytometer and seeded onto permeable 
polyethylene terephthalate (PET) filters (0.9 cm2 growth area; 0.4 µm pore size; 1.6 x 
106/cm2 pore density) at the base of BD Falcon cell culture inserts (BD Biosciences, 
Mississauga, ON, Canada) at a density of 0.5 x 106 cells/insert. Inserts were held in BD 
Falcon 12-well companion plates with inserts (apical side) and companion wells 
(basolateral side) containing 1 mL of medium each. 
3.3.2 Cell viability 
HDMEC were seeded in a 96-well plate and incubated with MTT (3-(4,55-
Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) (Sigma, St. Louis, MO) 
dissolved in PBS for 5 hours at 370C. DMSO was used to dissolve the precipitate formazan 
during the incubation, and a Multiskan Spectrum Spectrophotometer (Thermo Electron 
Corp) was used to detect concentration at 550 nm.  
3.3.3 IRE transfection 
HDMEC were first transfected with the IRE-CFP construct (Dongiovanni et al., 
2013) using LipofectamineTM 3000 Reagent (Invitrogen, Carlsbad, CA, USA) according to 
the manufacturer’s protocol, and then treated with iron. The fluorescent signal was 
normalized to the transfected-control group. Exposing the cells to iron increased CFP 
fluorescence. This was followed by selection with 50 ug/ ml Neomycin (Sigma-Aldrich, 
Oakville, ON, CA) for 24 hours. 
3.3.4 Iron detection by immunofluorescence 
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Half an hour prior to the end of iron treatment, cells were treated with 250 
µM ferrous sulfate (FeSO4; Sigma, St. Louis, MO), 3 µM Phen Green SK (PGSK) or 5 µM 
of CellRox Deep Red reagent (Invitrogen, Waltham, MA). Cells were then fixed with 4% 
PFA (Sigma, St. Louis, MO) followed by quenching with 1% glycine, and permeabilized 
with 0.1% Triton X- 100 (Bioshop, Burlington, ON). A control group at each time point 
was included in fluorescence quantification. 
3.3.5 Animal protocols 
Wild type (WT) male C57BL6 mice (Jackson Laboratory, Bar ME) were purchased 
at 8 weeks of age and were housed for one week of acclimatization in the facilities prior to 
experimentation (12h/12h light/dark cycle). Intraperitoneal injection of 10 mg of iron 
dextran (Santa Cruz, Dallas, TX) per 25g body weight was injected on a 5 day/week 
schedule for a duration of 4 weeks with a total volume of 300 µL per injection. 10% 
dextrose (Sigma, St. Louis, MO) was injected as a placebo. All mice were given chow diet. 
Individual mice were kept in the comprehensive lab animal monitoring system (metabolic 
cage) for 3 days for measurement of metabolic parameters. Night time data were recorded 
between 7:00 PM and 6:00 AM, day time data collected between 7:00 AM and 6:00 PM. 
All experiments were approved by the Animal Care and Use Committee at York 
University. 
3.3.6 Glucose and insulin tolerance test 
Animals were fasted prior to tolerance testing (6 hrs for insulin tolerance test, 16 
hours for glucose tolerance test). Mice were i.p. injected with glucose at 2g/kg of body 
weight. Blood glucose was recorded over a period of 120 minutes at times 0, 20, 30, 60 90, 
and 120 minutes post-injection. For the Insulin Tolerance Test (ITT), mice were i.p. 
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injected with insulin at 1 unit/kg of body weight. Blood glucose was recorded over a period 
of 80 minutes with 10 minutes intervals. Blood glucose was measured via saphenous vein 
bleed using a sterile needle (25G) and glucometer (Accu-Chek). Plasma was collected for 
analysis of adiponectin and insulin using ELISA kit (AIS, Hong Kong).  
3.3.7 Intracellular Iron 
Lysates were added to iron releasing agent (equal volume of 1M HCl and 4.5% 
KMnO4) and incubated at 600C for 2 hours. After incubation, iron detection reagent 
(6.5mM ferrozine, 6.5mM neocuproine, 2.5M ammonium acetate, 1M ascorbic acid; 
Sigma, St. Louis, MO) was added to samples and incubated at room temperature for 30 
minutes. A spectrophotometer was used to determine the iron concentration at 550 nm. A 
standard curve was generated, and the amount of iron was normalized to protein 
concentration of the lysate.  
3.3.8 Prussian blue staining 
Tissues were embedded with O.C.T. compound (VWR, Radnor, PA) for Perl’s Prussian 
blue staining for localization of iron. Section of 5-microns thickness were treated with 5% 
HCl to liberate ferric ions, then treated with 5% potassium ferrocyanide to produce 
insoluble ferric ferrocyanide.  Sections were then counterstained with neutral red using the 
method previously described (Khan et al., 2004). 
3.3.9 Micro-CT quantification 
Mice were anesthetized using 5% isoflurane for imaging by Bruker micro-CT. The 
threshold was established using whole mice to determine total body and fat volume using 
CT analysis software. Visceral fat was determined by manually highlighting the regions 
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inside the mouse around the organs. Subcutaneous fat was calculated by subtracting 
visceral fat from the total fat.  
3.3.10 Glycogen content  
Briefly, skeletal muscles and liver were digested in 1M KOH. pH of digested 
muscles was adjusted to 4.8 before addition of acetate buffer and 0.5 mg/ml 
amyloglucosidase. Subsequently, glycogen was hydrolyzed overnight at room temperate. 
A spectrophotometer was used to determine the glycogen concentration at 340 nm (Fediuc 
et al., 2006).  
3.3.11 Western blot analysis  
HDMEC were lysed in a buffer containing protease and phosphatase inhibitor 
cocktail tablets (Sigma, St. Louis, MO) then heated to 95°C for 10 min. Equal amounts of 
protein frome ach sample were resolved by SDS-PAGE, transferred to PVDF membrane, 
blocked with 3% bovine serum albumin (BSA) in wash buffer, and then incubated 
overnight at 4°C with primary antibodies specific for the following proteins: pAkt Thr308, 
PEPCK, pGSKSer9. Antibodies were obtained from Cell Signaling Technology (New 
England Biolabs Ltd., Whitby, ON, CA). Protein expression was normalized to GAPDH 
protein abundance. 
3.3.12 Statistical analysis 
All data are expressed as mean values ± SEM (n), where n represents the number 
of independent experiments conducted, except in Fig. 3 where n represents the number of 
inserts sampled from 1 out of 3 independent experiments conducted with equivalent results. 
A two-way analysis of variance (ANOVA) test was used to determine significant 
differences (p≤0.05) between groups. When appropriate, a Student’s t-test was also used. 
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All statistical analyses were conducted using Prism 6 software (GraphPad Software, La 
Jolla, California, USA). 
3.4 Results 
3.4.1 Iron overloaded HDMEC showed increased ROS but no change in adiponectin 
movement  
To create an IO (iron-overload) endothelium model, we used 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay to determine the iron concentration at 
which the cells’ viability will reduce significantly. MTT is a compound that gets reduced 
into a purple dye by AD(P)H-dependent oxidoreductase in a living cell. Therefore, a lower 
reading at OD550 nm indicates less cell viability, or conversely, more cell death. We found 
that starting from 500 uM treatment of iron for 48 hrs, the cell showed significantly reduced 
viability and 250 uM was therefore chosen for further experiments. 500 µM hydrogen 
peroxide was used as a positive control (fig. 1A). Furthermore, we found that iron 
accumulation was the highest in HDMEC after 48 hrs using the 250 uM treatment (fig. 
1B).  
 To confirm iron has an effect in HDMEC, we transfected HDMEC with an Iron 
Response Element (IRE)-CFP (cyan fluorescent protein) fusion construct. IRE is a short 
stem-loop sequence that is found on the mRNA of ferritin (iron storage protein). High 
concentration of iron causes an increase in transcription and translation of CFP (Meehan 
and Connell, 2001). We then checked for green signal from the non-transfected, transfected 
control, and transfected cells treated with iron for 48 hrs (fig. 2A). The greater green 
fluorescent signal suggested the IRE was activated by the iron treatment, as the 
quantification showed an 3.6-times enhanced signal (fig. 2B). To further confirm iron did 
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accumulate inside HDMEC, we used PGSK, which is a fluorescent dye that accumulates 
intracellularly and gets quenched by iron. The green fluorescent signal was reduced by 3.5 
times in the iron-treated group (fig. 2C), as confirmed by quantification (fig. 2D), showing 
that iron did accumulate inside the cells. 
We hypothesized that iron could potentially alter endothelium tightness via reactive 
oxygen species (ROS) production. To confirm this theory, CellRox Red was used to detect 
ROS elevation induced by iron. It is a cell-permeant dye that is non-fluorescent in a reduced 
state, however, upon oxidation by ROS it exhibits fluorescence. We saw a significant, 1.46-
time increase in ROS after 48 hrs of iron treatment (fig. 3A,B). As a functional effect of 
iron, we checked for transepithelial electrical resistance (TEER), an indicator of 
endothelium tightness. If the TEER decreased, it suggested that the endothelium is leakier 
and more hormones will able to access the tissue. After 48 hrs, the tightness of control 
HDMEC was determined to be 36.40 ± 2.14 Ω*cm2, while under iron treatment with 
tightness was 38.80 ± 2.56 Ω*cm2 (fig. 3C), hence there was no significant change in flux 
of fAd (fig. 3D,E.).  
3.4.2 Iron Overload (IO) Mice Showed Enhanced Glucose Clearance and insulin 
signaling  
As IO turned out to have no effect on endothelium tightness or Ad flux, we then 
further investigated how iron affects glucose metabolism in the whole body. To create an 
IO mouse model, we injected the mice with iron intraperiotneally five days per week for 
four weeks. After 4 weeks (10mg/ 25g body weight) of injection, we found circulating iron 
increased significantly from 16.08 ± 0.08 mM to 51.80 ± 6.0 mM (fig. 4A) in the iron-
treated mice. In order to characterize this new mouse model, we used a glucose tolerance 
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test (GTT) to evaluate the ability of the mice to use glucose. We found that IO mice have 
improved glucose clearance, corresponding to a lower area under the curve (28%) 
compared to control mice (fig.4D,E). IO also exhibited better insulin sensitivity, as there 
was an approximate 23% reduction in the area under the curve from the insulin tolerance 
test compared to controls (fig. 4F,G).  
As validation of this model, iron accumulation was also shown in various skeletal 
muscle tissues. In tibialis anterior muscle (TA), control mice displayed and iron 
concentration of 0.42 ± 0.024 mM/ug protein compared to 0.79 ± 0.13 mM/ug protein in 
IO mice (fig. 5A,B). Similar observations were made in gastrocnemius muscles (Gas), 
where control mice accumulated 0.34 ± 0.04mM/ug, whereas IO mice deposited 0.58 ± 
0.054 mM/ug protein (fig. 5C,D). Furthermore, as compared to other skeletal muscles, 
soleus (sol) accumulated the least iron at 0.71 ± 0.043mM/ug protein, but this was still 
higher than the control mice at 0.57 ± 0.01 mM/ug protein (fig. 5E,F). The change in iron 
accumulation in muscles was further confirmed by Prussian blue histology from isolated 
muscles. Interestingly, we also found that control mice had a body weight of 24.67 ± 0.49 
g, but weight was reduced to 21.67 ± 0.56 g  after 4 weeks injection in the IO group (fig. 
6A). Circulating adiponectin was reduced from 28.36 ± 1.16 ug/ml to 16.91 ± 0.56 ug/ml 
in the IO mice compared to control (fig. 6B) However, circulating insulin in control was 
1.83± 0.01ng/ml and did not change significantly in the IO condition, reaching 1.84 ± 0.01 
ng/ml (fig. 6C).  
3.4.3 IO mice showed no change in activity  
To further characterize this IO mouse model, activity level along with other metabolic 
parameters were measured using Comprehensive Lab Animal Monitoring System 
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(CLAMS) for a 3 day period. All mice had free access to food and water and were subjected 
to light-dark cycle. 
The mice showed a characteristically higher CO2 elimination and O2 consumption at night, 
compared to the day (fig. 7A,B), as further quantified in fig. 7C,G, reflecting the normal 
nocturnal activity of mice. Thus, their respiratory exchange ratio was also higher at night 
(fig. 8A,B). IO mice were found to be less active (20%), and produced less heat as 
compared to the control mice (fig. 9A,B), as quantified in fig. 9C,D.  
3.4.4 Effect of iron on skeletal muscles 
There are various tissues responsible for glucose utilization; therefore we wanted 
to determine the tissue-specific effect and molecular mechanism responsible for the 
enhanced glucose tolerance observed in IO mice. We first looked at skeletal muscles since 
they are the main sites for glucose disposal. We isolated TA, gastro and sol and examined 
phosphorylation of Akt and GSK, downstream kinases of insulin receptor signaling (fig. 
10). We found gastro had an increase in Akt phosphorylation under insulin-stimulated 
conditions (fig. 10B), as shown in a representative blot (fig. 10G).  
The amount of glucose being converted into glycogen also could explain the IO 
mouse phenotype. However, there was no significant difference in glycogen content in 
tissues from IO mice as compared to the control group (fig. 11A-C) 
3.4.5 Effect of iron on liver metabolism  
The liver is an important metabolic organ and is the major site for iron storage. Iron 
concentration was quantified by intracellular iron assay showing control mice had 0.20 ± 
0.02M/ug protein, which was increased significantly to 3.25 ± 0.49M/ug protein in the IO 
mice.  Iron accumulation was further confirmed by Prussian blue staining (fig. 12A,B). 
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Corresponding to the iron accumulation, the liver enlarged from 0.93 ± 0.01 g to 1.9 ± 0.09 
g with IO (Fig. 12C,D). Iron did not have an effect on the insulin signaling pathway, as 
shown by no change in insulin-stimulated Akt phosphorylation or PEPCK expression in 
the liver (Fig.12E,F). Furthermore, there was no significant difference in glycogen content 
in the livers isolated from IO mice (fig.11D) 
3.4.6 Iron diminished fat content  
To understand the cause of the lower body weight and body fat in IO mice, we 
examined their daily food intake and energy expenditure together. We isolated two 
different fat depots to study the change in fat composition in the IO condition. We isolated 
perirenal (peri) and epididymal (epi) fats to represent visceral fat. The weight for epi fat 
reduced from 0.39 ± 0.07 g to 0.02 ± 0.01 g (fig. 13B). Peri fat had an average weight of 
0.15 ± 0.03 g (fig.13C) under control conditions, but could not be detected in the IO 
condition. Furthermore, weight of isolated fat from the inguinal region, representing 
subcutaneous fat (Sub), did not change; control mice weighed an average of 0.29 g ± 0.02 
and this was not significantly changed in IO mice at 0.26 ± 0.03 g (fig. 13A).  Since 
subcutaneous fat is another tissue that accumulates iron, we also quantified iron 
accumulation in this depot. Under control conditions sub fat had 0.67 ± 0.03 mM/ug 
protein, which was increased to 2.61 ± 0.36 mM/ug protein in IO (fig. 13D). This 
observation was also reflected in Prussian blue histology staining (fig. 13E). The reduction 
in fat is reflected in the computerized tomography (CT) scan (Fig. 13F) and body weight 
(Fig. 6A). Total body fat volume reduced from 717.6 ± 38.87 to 143.5 ± 22.96 mm3 in IO 
(fig. 14B). Hence, total percentage body fat reduced from 10.60 ± 0.62 to 2.30 ± 0.36 in 
IO condition (fig. 14A). Quantification of the volume of each fat depot showed a reduction 
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of both subcutaneous fat (from 548.9 ± 29.55 mm3 to 122.5 ± 19.36 mm3) and visceral fat  
(from 168.7 ± 14.00 mm3 to 20.99 ± 5.23 mm3) in IO (fig.14C,D). Interestingly, on average 
per day IO mice had no difference in food consumption (4.66 ± 0.47 g) as compared to 
control mice (4.38 ± 0.83 g) (fig. 13G).  
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Figure 1: Characterizing the HDMEC IO model. A) Determining treatment dose. Different 
doses of iron was applied to HDMEC. MTT is a dye which is reduced into a purple dye by 
AD(P)H-dependent oxidoreductase in a living cell. Hydrogen Peroxide was used as 
positive control for cell death. 250 uM is the concentration used for further experiments. 
B) Determining treatment time. Time-course showing accumulation of intracellular iron. 
HDMECs were treated with 250 uM of iron over a period of 48 hrs to determine treatment 
time. Amount of iron was normalized to protein concentration of the cell lysate. We 
determined HDMEC would be treated for 48 hrs to create an IO model. Data are expressed 
as mean values ± SEM (n = 3). Two-way ANOVA was used comparing treatment group to 
control (fig. A) or at t0 (fig. B). * indicates significant difference (p ≤ 0.05) from control 
group.   
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Figure 2: Further confirmation of the IO HDMEC model using iron response element 
(IRE) and Phen Green SK (PGSK). A) Confirmation of IO in HDMEC by IRE-CFP 
construct. Representative images for HDMEC transfected with IRE-CFP. Cells were 
transfected with IRE-CFP construct then treated with iron. Fluorescent signal was 
normalized to transfected- control group. Exposing the cells to iron increased CFP 
fluorescence. B) Quantification of (A). C) Representative images for PGSK. PGSK is a 
fluorescent dye that accumulates intracellularly and gets quenched by iron. D) 
Quantification obtained from total green fluorescence per field of view. 5-10 images 
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were used per n number.  Data are expressed as mean values ± SEM (n = 3). Two-way 
ANOVA and  Student’s t-test were used. * indicates significant difference (p ≤ 0.05) 
from control group. 
 
 
 
Figure 3: The effects of iron on HDMEC monolayer. A) Representative image of reactive 
oxygen species (ROS) upon iron treatment. CellRox Red is a dye that becomes fluorescent 
upon oxidation by ROS. 5 uM of CellRox Deep Red reagent was added half an hour before 
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iron. B) Quantification of A. Total red signal in the field of view was normalized to total 
DAPI signal in that field of view. 5-10 images were used per n number.  C) TEER after 48 
hrs iron treatment. E) adiponectin flux after 48 hrs iron treatment by western blots. Data 
are expressed as mean values ± SEM (n = 3-4). Two-way ANOVA and Student’s t-test were 
used. * indicates significant difference (p ≤ 0.05) from control group.  
 
 
Figure 4: Characterizing IO mouse model. Mice were intraperitoneally (i.p.) injected with 
iron for 4 weeks, 5 days per week at 10mg/ 25g of body weight to generate the IO model. 
Control mice were i.p injected with 10% dextrose. A) Circulating iron. Serum was used to 
test for circulating iron. B) Secreted glucose (non- fasted) determined in urine. C) Secreted 
glucose (fasted) determined in urine. D) Glucose Tolerance Test (GTT). Mice were i.p 
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injected with glucose at 2g/ kg of body weight. Blood glucose was recorded over period of 
120 minutes at indicated times. E) Quantification of GTT, area under the curve. F) Insulin 
Tolerance Test (ITT). Mice were i.p injected with insulin at 1 unit/kg of body weight. Blood 
glucose was recorded over period of 80 minutes at indicated times. G) Quantification of 
ITT, area under the curve. Data are expressed as mean values ± SEM (n = 3-9). * indicates 
significant difference (p ≤ 0.05) from control group. Student’s t-test was used. 
 
 
Figure 5: Iron accumulation in IO mouse skeletal muscles. Tissues were isolated after 4 
weeks injection with or without iron. Tissue lysates were used to detect intracellular iron. 
Amount of iron was normalized to protein concentration. A) Iron accumulation in tibialis 
anterior (TA) muscle. C) Iron accumulation in gastrocnemius (gastro). E) Iron 
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accumulation in soleus (sol). B,D, F) Representative images for Prussian blue staining in 
TA, gastro and sol. Data are expressed as mean values ± SEM (n = 3). * indicates 
significant difference (p ≤ 0.05) from control group. Student’s t-test was used. 
 
 
 
 
 
Figure 6: Hormonal changes in IO mice. A) Mouse body weight after 4 weeks of dextrose 
(Con) or iron injection. B) Circulating fAd. Mouse adiponectin (fAd) ELISA kit was used 
to detect serum fAd. C) Circulating insulin. Mouse insulin ELISA kit was used to detect 
serum insulin. Data are expressed as mean values ± SEM (n = 3-9). * indicates significant 
difference (P ≤ 0.05) from control group. Student’s t-test was used. 
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Figure 7: Characterizing IO mouse respiration. Individual mice were kept in the 
comprehensive lab animal monitoring system (metabolic cage) for 3 days for measurement 
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of numerous metabolic parameters. Night time data were recorded between 7:00 PM and 
6:00 AM, day time data collected between 7:00 AM and 6:00 PM. A) Oxygen (O2) 
consumption. Data were collected as total amount of oxygen consumed by individual mice 
per hour then expressed as an average per hour for all 3 days for all animals. B) Carbon 
dioxide (CO2) elimination. Data were collected as total amount of carbon dioxide 
eliminated by individual mice per hour then expressed as an average per hour for all 3 
days for all animals. C) Quantification of O2 consumption. Data expressed as an average 
of total O2 consumed for all 3 days.  D) Quantification of CO2 elimination. Data expressed 
as an average of total CO2 eliminated for all 3 days. Data are expressed as mean values ± 
SEM (n = 6-7). Two-way ANOVA was used comparing during day or night between groups. 
* indicates significant difference (p ≤ 0.05) from control group.  
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Figure 8: IO mouse Respiratory Exchange Ratio.  A) Respiratory Exchange Ratio. Data 
were calculated by taking the ratio of total carbon dioxide eliminated over oxygen 
consumed by individual mice per hour then expressed as an average per hour for all 3 days 
for all animals. B) Quantification of respiratory exchange ratio. Data expressed as 
averaged ratio over 3 days. Data are expressed as mean values ± SEM (n = 6-7). Two-way 
ANOVA was used comparing during day or night between groups. * indicates significant 
difference (p ≤ 0.05) from control group.  
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Figure 9: Characterizing IO mouse phenotype. Individual mice were kept in the 
comprehensive lab animal monitoring system (metabolic cage) for 3 days for measurement 
of numerous metabolic parameters. A) Total ambulatory activity. Data were collected as 
total number of beam breaks (step counts) by individual mice per hour. This was then 
expressed as an average per hour from all animals for all 3 days. B) Heat production. Data 
was collected as total heat production per hour by individual mice, then expressed as an 
average per hour for all 3 days for all animals. C) Quantification of total ambulatory 
activity. Data expressed as an average of total step counts for all 3 days. D) Quantification 
of heat production. Data expressed as an average of total heat production for all 3 days 
for all animals.  Data are expressed as mean values ± SEM (n = 6-7). Two-way ANOVA 
was used comparing during day or night between groups. * indicates significant difference 
(p ≤ 0.05) from control group.  
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Figure 10: Insulin signaling under IO conditions. Tissues were isolated after 4 weeks of 
iron injection. Mice were injection with 4U/ kg of insulin 5 minutes prior isolation of 
tissues. A-C) pAkt expression. A) TA. B) Gastroc. C) Soleus. D-F) pGSK expression. D) 
TA. E) Gastroc. F) Soleus. G) Representative western blots. Data are expressed as mean 
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values ± SEM (n = 3). * indicates significant difference (p ≤ 0.05) from control group. 
Student’s t-test was used. 
 
 
Figure 11: Glycogen content in skeletal muscles and liver. A) TA. B) Gastroc. C) Soleus. 
D) Liver. Data are expressed as mean values ± SEM (n = 3-5). Data are expressed as mean 
values ± SEM (n = 3). * indicates significant difference (p ≤ 0.05) from control group. 
Student’s t-test was used. 
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Figure 12: Effects of iron on the liver. A) Intracellular liver iron content. B) Prussian blue 
staining for iron. C) Isolated liver weight. D) Isolated liver. E) PEPCK protein abundance. 
F) pAkt308 protein abundance G) representative blots for PEPCK protein. H) 
representative blot for pAkt308. Data are expressed as mean values ± SEM (n = 6-7). Data 
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are expressed as mean values ± SEM (n = 3). * indicates significant difference (p ≤ 0.05) 
from control group. Student’s t-test and two-way ANOVA were used. 
 
 
Figure 13: Effects of iron on fat content. A) Weight of isolated subcutaneous fat from the 
inguinal region. B) Visceral fat- epididymal (epi) weight. C) visceral fat- perirenal (peri) 
weight. D) intracellular iron. E) Prussian blue staining for iron detection. F) micro-CT 
scan images. G) micro-CT scan quantification H) food intake. Data are expressed as mean 
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values ± SEM (n = 3-4). * indicates significant difference (p ≤ 0.05) from control group. 
Student’s t-test was used. 
 
Figure 14: Micro-CT quantification. Threshold was determined using whole mice to find 
the total body and fat volume using CT. Visceral fat was determined by manually 
highlighting the regions inside the mouse around the organs. Subcutaneous fat was 
calculated by subtracting visceral fat from the total fat. A) total percentage body fat. B) 
Total fat volume. C) Visceral fat volume. D) Subcutaneous fat volume. Data are expressed 
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as mean values ± SEM (n = 3). * indicates significant difference (p ≤ 0.05) from control 
group. Student’s t-test was used. 
 
 
Figure 15: Summary the effects of iron on different tissues.  
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3.5 Discussion  
We validated the HDMEC IO model using multiple methods including PGSK and 
IRE-CFP, and used this model for monitoring alterations in Ad movement (fig. 2). We 
concluded from our study, which consisted of 48 hrs of iron treatment, that transport of 
hormones did not alter, because there was no change in TEER or movement of Ad across 
the endothelium (fig. 3D,E). We further elucidated whether iron has an impact on 
metabolism in an animal model by creating an IO mouse model to investigate the effect of 
iron on metabolism. This model mimicked genetic HH disease. We successfully elevated 
iron levels in the blood (Fig. 4A) and iron accumulation in various skeletal muscles and fat 
(fig. 5). Our observation by GTT and ITT was that IO mice had better glucose clearance 
(fig. 4D,F). This contradicted previous findings that chronic IO results in decreased glucose 
clearance (Dongiovanni et al., 2013; Yu et al., 2015). Insulin signalling was enhanced in 
gastroc, as determined by pAkt activation that was stimulated by insulin (fig. 10B). Akt is 
involved in the regulation of many cellular functions including energy metabolism, cell 
proliferation, and apoptosis. The PI3K pathway is a key component in the regulation of 
glucose metabolism. Currently, there are no reports of enhancing pAkt activation in 
skeletal muscle under IO condition. However, in mouse hippocampal neurons, studies have 
shown the presence of iron caused an increase in the phosphorylation level of Akt in a 
PI3K-dependent manner. Additionally, nuclear localization of PI3K and Akt increased 
upon iron treatment as shown by immunohistochemistry. In contrast, nuclear localization 
of GSK3β decreased in the presence of iron (Uranga et al., 2013). This could potentially 
explain why phosphorylated Akt was unable to activate GSK3β via direct phosphorylation. 
With the currently accepted model of Akt phosphorylation/activation in skeletal muscle, 
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Akt is translocated from the cytoplasm and activated at the inner leaflet of the plasma 
membrane, rather than in the nucleus as shown in mouse hippocampal neurons (Motti et 
al., 2004; Santi and Lee, 2010; Zhou et al., 2001), Hence, further immunohistochemistry 
could be performed to confirm the hypothesis of GSK translocation by using MAPK/ERK 
as nuclear and cytosolic markers. Despite the GSK translocation theory, a glycogen content 
assay is needed to further confirm the functional effect of iron on GSK-3β activity. We 
speculated the lower blood glucose level resulted in more glycogen production in both liver 
and muscles. Hence, we examined the effect of iron-induced protein kinase activation on 
glycogen metabolism. Previous studies show that chelation reversed iron’s effect on insulin 
signaling by increasing pAkt and GSK-3β, therefore enhancing glycogen synthesis in the 
liver (Dongiovanni et al., 2008). Interestingly, there was no change in GSK-3β 
phosphorylation or glycogen content in either skeletal muscles or liver in the current study 
(fig. 11). 
  Mouse activity level was tested as a potential contributor to lowered blood glucose 
levels, as blood glucose would decrease when the mice are active.  Thus we hypothesized 
that enhanced glucose clearance observed in IO mice was due to higher physical activity. 
A group of researchers previously used genetic IO and found these mice had better glucose 
tolerance (Huang et al., 2007). The study concluded that increased glucose disposal does 
not result from increased insulin action. Instead, these mice demonstrated increased Ad 
levels and activation of AMPK. However, AMPK level can be closely associated to the 
activity of the mice; if the mice are more active, pAMPK increases (Huang et al., 2007). 
We utilized metabolic cages to confirm whether the IO mice are more active as compared 
to the control. If they have normal activity compared to control mice, we could explain the 
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phenotype using AMPK activity level (Huang et al., 2007). When they are more active, 
pAMPK is usually increased (Huang et al., 2007), hence decreasing blood glucose. 
Interestingly, IO mice did not exhibit higher activity compared to control mice (fig. 9). 
Circulating levels of insulin did not change with IO (fig. 6C). Furthermore, 
circulating Ad was reduced by almost half (fig. 6B), potentially due to a significant 
reduction in visceral fat (fig.13B,C, 14C). Therefore, the observed effect in this study is 
limited. 
There is a strong link between iron overload and kidney dysfunction.  As reported 
from clinical studies, urine analysis of β-thalassemia patients had higher albumin and β2-
macroglobulin, as well as higher NAG activity, which are positively correlated with serum 
ferritin and iron deposition (Koliakos et al., 2003).  Hence, we tested whether iron affects 
glucose excretion. We observed an increased urine glucose level in mice in the non-fasted 
state after iron injection. Under basal conditions, iron-injected mice secreted more glucose, 
similar to the STZ-induced diabetic condition (Montilla et al., 2005). This observation 
suggested that iron treatment can have a diuretic effect and may eventually lead to iron-
induced diabetic nephropathy in these mice if the injection was to continue further. Renal 
failure could possibly have contributed to lowered blood glucose levels. Furthermore, as 
kidneys play a major role in glucose homeostasis through reabsorption via the sodium 
glucose cotransporter (SGLT) (Kalra et al., 2016), down-regulation of SGLT could 
potentially explain the increased glucose excretion.  
Phosphoenolpyruvate carboxylase (PEPCK), a protein that regulates blood glucose 
levels through hepatic glucose production, is supressed by an anti-diabetic substance 
(D_xylose), hence reducing glucose production in the liver on top of enhancing the 
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regeneration of pancreas tissues to increase insulin levels. Therefore, these mice have better 
glucose clearance by enhanced glucose uptake (Kim et al., 2016). The basal level of 
PEPCK after iron treatment did not change (fig. 12G). Therefore, the lower blood glucose 
(enhanced glucose clearance) was not due to supressing glucose production or secretion by 
the liver under IO conditions. The synthesis of glucose into glycogen in the liver 
contributes to the regulation of circulating glucose levels (Irimia et al., 2010). The 
improved glucose clearance might be a homeostatic strategy for the liver to compensate 
for the effects of excess iron. In mice with type 2 diabetes, treatment with obestatin showed 
improved insulin sensitivity and reduced liver mass, while glycogen content was higher in 
these obestatin treated mice (Kolodziejski et al., 2017).  
Adipocytes are known for their function to store energy, and play an important role 
in energy balance. To further examine the role of adipocytes as regulators of energy balance 
in IO, we demonstrated that iron accumulated in fat tissue (fig. 12D,E), which may be due 
to an increase in hepcidin expression levels, as reported in cultured adipocytes (Andrews 
and Arredondo, 2012). IO mice induced a lipodystrophy-like condition, a heterogeneous 
autosomal recessive disorder that results in abnormal and degraded adipose tissues. 
Lipodystrophies are often associated with loss of subcutaneous adipose tissue and increase 
in visceral fat mass, and they exhibit pathophysiology of insulin resistance and abnormal 
triglyceride metabolism (Akpinar et al., 2015). However, the fat loss observed in IO mice 
was limited to the visceral depot, which is the opposite of lipodystrophy. Hence, lipolysis 
is likely a more accurate word to describe the observation. A similar observation was 
reported in cultured adipocytes, where iron increased lipolysis (Rumberger et al., 2004). 
The fat loss induced by IO was partial/selective rather than whole body. Only visceral fat 
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was affected in these IO mice. There were reports that patients with lipodystrophy had 
higher circulating levels of free fatty acids. Under normal conditions, adipocytes enlarge 
and store more triglycerides (TG).  However, in patients that lack adipocytes, the excess 
TG gets stored in liver and skeletal muscles. This abnormal TG storage will eventually lead 
to insulin resistance and its complications (Muniyappa et al., 2014; Petersen et al., 2002).  
 This loss in fat induced by iron is responsible for the reduction in circulating Ad, 
similar to previously reported data (Gabrielsen et al., 2012).  The elevated iron level might 
impair the Ad signalling pathway, hence leading to the onset of diabetes. Iron chelation 
therapy with desferrioxamine and deferiprone has significantly increased Ad levels in β-
thalassaemia patients (Chaliasos et al., 2010).  
In summary, acute IO did not affect circulating insulin levels. However, Ad levels 
were reduced by half. This phenotype might be an indicator of impaired Ad signalling 
induced by excessive iron. This IO model can be a potential tool for studying the underlying 
mechanisms in the progression of diabetes induced by iron. In adipose tissue, the DNA-
binding protein high mobility group box 1 (HMGB1) was shown to be a pro-inflammatory 
mediator by releasing cytokines such as tumor necrosis factor-α (TNF-α) and promoting 
immune cell activation. Activated immune cells including macrophages secrete additional 
HMGB1 to further recruit additional immune cells. It has been demonstrated in obese mice 
that immune cell infiltration in adipose tissue contributes to the development of type 2 
diabetes by supressing insulin-stimulated Akt phosphorylation (Feuerer et al., 2009; Winer 
et al., 2009). Adipose tissue dysfunction is considered as one of the main causes of diabetes. 
Future experiments to understand macrophage infiltration are needed, as it has been 
demonstrated that increased inflammatory cells in visceral adipose tissue impair adipocyte 
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function by reducing lipogenesis and increasing lipolysis (McGillicuddy et al., 2009; Souza 
et al., 2003). Current experiments may explain the observable decrease in fat tissue. 
Furthermore, the phenotype could be explained by six transmembrane protein of prostate 
2 (STAMPS), a protein that is well known for its anti-inflammatory role and maintaining 
normal glucose level.  Previous studies have shown overexpression of STAMPS reduced 
adipocyte size in obese mice (Wang et al., 2017). Hence, measuring adipocyte size can also 
be a good indicator for the progression of diabetes in these IO mice.  
Lastly, previous research has shown the antioxidant role of activated Akt against 
oxidative stress that is induced by iron via an increase in ROS production.  Such cells 
exhibited higher ROS levels when treated with a combination of iron and LY294002 (an 
Akt inhibitor), as opposed to treatment with iron alone. Conversely, using a cell line 
overexpressing Akt, it was possible to observe a reduction in ROS, hence protecting the 
cells from oxidative stress (Uranga et al., 2013).  Oxidative stress has been considered a 
main contributor to impaired insulin signaling.  Multiple experimental approaches have 
lead to the suggestion that the PI3K/Akt pathway is the initial response in preventing the 
negative effect of increasing cellular ROS levels generated by iron exposure. The mice 
under iron treatment will potentially progress to insulin and adiponectin resistance. Hence, 
early protection against excessive iron is required to arrest the progression and the 
deleterious effects. Such prevention can include the use of iron chelator, as clinical studies 
have demonstrated the effectiveness of iron chelation on the maintenance of normal 
glucose tolerance (Cooksey et al., 2010).   
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Chapter 4: Conclusion 
4.1 Summary of research  
I started my Masters research using HUVECs as a model. They are considered to 
have a leaky endothelium due to its venous derivation, and have been used in many studies 
to examine the effect of Dex (Goodwin et al., 2013; Wang et al., 2015). More recently, we 
used what we believe is a more physiologically relevant model, HDMEC. Since the 
microvascular complications of diabetes such as diabetic retinophaty, are well-known 
(Sacks et al., 2014). As HDMEC is also a tighter endothelium model compared to HUVEC, 
we hypothesized that we would be better able to see a change if iron causes the endothelium 
to be leakier. Regardless, they both are good representative models of endothelium.  
Our study indicated that glucocorticoid-mediated tightening of endothelium can 
reduce flux of Ad across endothelial monolayers, and that this may be due to alterations in 
the expression profile of tight junction proteins. Furthermore, in a rat model of diabetes 
induced by exogenous glucocorticoids, we observed reduced interstitial and intracellular 
levels of Ad in skeletal muscle. Thus, we propose that reduced Ad action in target tissues, 
as a consequence of reduced endothelial flux from circulation to interstitial space, may 
contribute to the diabetic phenotype occurring after glucocorticoid treatment. Since 
glucocorticoids are one of the most commonly prescribed medications, our discovery of 
reduced Ad transport in response to glucocorticoids is a particularly important and novel 
finding with potentially far-reaching consequences, leading to the rationale for a second 
project to study whether iron could regulate endothelium Ad movement, hence altering 
glucose metabolism. Using a more physiologically-relevant iron overload HDMEC model, 
we have found that iron did not change the endothelium tightness nor Ad movement to the 
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target tissues, despite the elevated ROS production. To further elucidate the effect of iron 
on whole body glucose metabolism, we have successfully created an IO mouse model. I 
have found these mice have better glucose clearance compared to the control mice. We 
proposed that the underlying mechanism involved an upregulation of pAkt and constant 
excretion of glucose through in the urine as a compensatory mechanism to lower blood 
glucose. Additionally, we have shown that circulating Ad is reduced by half whereas 
insulin level was not affected by iron treatment.  
4. 2 Future directions  
 
Iron overload has been well established as a contributor to the development of 
insulin resistance and impairment of glucose metabolism, which is characteristic of 
metabolic disorders such as type 2 diabetes (Rumberger et al., 2004). In addition, research 
has shown the antioxidant role of activated Akt against oxidative stress induced by iron via 
the increase in ROS production.  The cells showed much higher ROS levels when using a 
combination of iron and LY294002 (an Akt inhibitor) compared to treatment with iron 
alone. However, using a cell line overexpressing Akt, they were able to observe a reduction 
in ROS, hence protecting cells from oxidative stress (Uranga et al., 2013).  Oxidative stress 
has been long considered a main contributor to impaired insulin signaling.  This group also 
used multiple approaches to show the protective role of the  PI3K/ Akt pathway as the 
initial response in preventing the negative effect of increased cellular ROS levels generated 
by iron exposure. These mice will potentially progress to insulin and Ad resistance if iron 
treatment is sustained, hence an early prevention is required (Uranga et al., 2013).  Clinical 
studies have shown the effectiveness of using an iron chelator as treatment in obese mice, 
allowing maintenance of normal glucose tolerance (Cooksey et al., 2010). Hence, given 
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the importance of pAkt, I would like to repeat Western blots for pAkt to confirm previous 
protein abundance observations. Furthermore, total Akt is required as loading control to 
see the effect of iron on basal Akt. Also, I would like to check GLUT4 translation using 
immunofluorescence, as this is the key protein involved in intracellular insulin signalling, 
downstream of pAkt (Takenaka et al., 2014). Finally, I would like to evaluate glucose 
uptake in this mouse model using radioactive tracer (Ishino et al., 2017).  
An additional finding in my study was that Ad levels are reduced by half, in 
association with diminished fat content. The same observation was reported in cultured 
adipocytes where iron increased lipolysis (Rumberger et al., 2004). Furthermore, iron 
overload reduced the abundance of adipocyte iron export channel (ferroportin), leading to 
decreased Ad and insulin resistance. Hence, for future studies, a time course iron treatment 
(1, 2, 3 weeks) to study the effect of iron on adipocytes and insulin resistance, characterized 
by mRNA and protein abundance, can be highly beneficial. This future study will help 
address and target the key stages in preventing the deleterious effect of excess iron.  
Finally, kidneys isolated from IO mice could be an important target, as kidneys play 
a major role in glucose homeostasis through glucose reabsorption via sodium glucose 
cotransporter (SGLT). In diabetic patients, the SGLTs gene is upregulated (Kalra et al., 
2016). Therefore, SGLT protein abundance may confirm the underlying mechanism that is 
responsible for glucose excretion.  
 
4.3 Concluding remarks  
In conclusion, my in vitro and in vivo studies present the importance of Ad access 
to target tissues in altering glucose metabolism. My studies have suggested the mechanism 
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through which iron enhanced glucose clearance via upregulation of Akt phosphorylation 
and glucose excretion. With the future plans, I hope to provide more insight into the 
underlying mechanism that is responsible for the enhanced glucose clearance, as well as 
identify potential targets for diabetes therapies.   
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